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Hodgkin lymphoma (HL) is a unique entity where the fraction of malignant cells accounts for 
only 1 % of the tumor. The cells are embedded in a complex background of non-neoplastic 
immune infiltrates. Profound interactions of the malignant cells with neighboring cells are a 
requisite to sustain their survival and allow tumor development. Among the cell types 
commonly found in the HL tumor mass are macrophages whose presence has been associated 
with poor prognosis. Macrophages are innate immune cells and critical regulators of immune 
responses and tissue remodeling. They are known to occur in all cancer types where they 
exhibit various functions to promote tumor growth and metastasis. This study aims to gain a 
deeper insight into the interplay of HL cells with macrophages. 
Herein, we show that HL cells actively recruit macrophages. Using Boyden chamber assays we 
found that monocytes and macrophages migrate toward HL conditioned medium (CM). 
Applying CM directly on the cells further revealed that factors in the CM support the 
differentiation of monocytes into macrophages and macrophage repolarization. By the 
analyses of selected markers via flow cytometry and qRT-PCR we found that these 
macrophages expose an M2-like phenotype. A characteristic feature was their high CD206 
expression. Investigations into the functional consequence of high CD206 expression included 
endocytosis assays and revealed an enhanced uptake of CD206 specific targets. Alongside we 
found that macrophages secret high amounts of MMP-9 and alter the tumor formation of HL 
cells in a chorion allantois membrane assay. By applying selected factors on monocytes we 
found that the increased CD206 expression in HL derived macrophages could be a result of 
IL-13 produced by HL cells. Further analysis of the phenotype of HL derived macrophages 
included RNA sequencing and revealed an enrichment of upregulated genes involved in 
antigen presentation and as well co-stimulation and -inhibition. 
Taken together, these findings support a model in which HL cells secret factors to attract and 
generate macrophage with a specific M2-like activation state. Analyses of their phenotype and 





Abstract ................................................................................................................................... V 
List of figures .........................................................................................................................IX 
List of tables ...........................................................................................................................XI 
Abbreviations ....................................................................................................................... XII 
1 Introduction ..................................................................................................................... 1 
1.1 Macrophages ............................................................................................................. 2 
1.1.1 Macrophage origin and development ................................................................. 2 
1.1.2 Macrophage activation: The M1-M2 axis ............................................................ 3 
1.1.3 Tumor associated macrophages .......................................................................... 4 
1.2 The mannose receptor CD206 ................................................................................... 7 
1.2.1 The mannose receptor family ............................................................................. 7 
1.2.2 Expression and functions of CD206 .................................................................... 9 
1.3 Hodgkin lymphoma ................................................................................................. 10 
1.3.1 Clinical and molecular features of Hodgkin lymphoma ..................................... 10 
1.3.2 The microenvironment of classical Hodgkin lymphoma .................................... 12 
Aims of this study .................................................................................................................. 14 
2 Material and Methods .................................................................................................... 15 
2.1 Material, recipes and equipment ............................................................................. 15 
2.1.1 Cell lines .......................................................................................................... 15 
2.1.2 Primary material .............................................................................................. 15 
2.1.3 Chemicals, solutions and consumable supplies ................................................. 15 
2.1.4 Buffers and media ............................................................................................ 19 
2.1.5 Equipment ....................................................................................................... 21 
2.1.6 Stimulants and inhibitors ................................................................................. 23 
2.1.7 Antibodies ........................................................................................................ 23 
2.1.8 Oligonucleotides .............................................................................................. 24 
2.1.9 Ready to use reaction systems .......................................................................... 25 
2.1.10 Software .......................................................................................................... 26 
2.2 Cell biology ............................................................................................................. 27 
2.2.1 Cell culture ...................................................................................................... 27 
2.2.2 Isolation of human monocytes via double gradient centrifugation .................... 27 
VII 
 
2.2.3 Isolation of human monocytes via magnetic cell separation .............................. 28 
2.2.4 Differentiation of human monocytes to macrophages ....................................... 28 
2.2.5 Stimulation and inhibitor treatment of human monocytes ................................ 29 
2.2.6 Stimulation of macrophages ............................................................................. 30 
2.2.7 Flow cytometry ................................................................................................ 30 
2.2.8 Endocytosis assays ........................................................................................... 30 
2.2.9 Migration and invasion assay ........................................................................... 31 
2.2.10 Chick chorion allantois membrane assay .......................................................... 32 
2.2.10.1 Measurement of CAM tumor areas ............................................................ 33 
2.2.10.2 Scoring hemorrhages in CAM tumors ........................................................ 33 
2.2.10.3 Trichrome staining of CAM tumor sections ................................................ 33 
2.2.10.4 Peroxidase staining of CAM tumor sections ............................................... 34 
2.3 Protein biochemistry ............................................................................................... 35 
2.3.1 Detection of matrix metalloproteinase activity by zymography ......................... 35 
2.3.2 Enzyme-linked immunosorbent assay of M-CSF ................................................ 36 
2.4 Molecular biology ................................................................................................... 36 
2.4.1 mRNA isolation ................................................................................................ 36 
2.4.2 Reverse transcription........................................................................................ 36 
2.4.3 Quantitative real-time polymerase chain reaction ............................................. 37 
2.4.4 RNA sequencing ............................................................................................... 38 
2.5 Statistical analyses .................................................................................................. 38 
3 Results ........................................................................................................................... 39 
3.1 Monocytes migrate toward cHL secreted factors ...................................................... 39 
3.2 Monocytes differentiate into macrophages in the presence of lymphoma CM ........... 40 
3.3 L-428 CM derived macrophages strongly resemble an M2 phenotype ...................... 43 
3.3.1 Analysis of cell surface markers on M-CSF and L-428 CM differentiated 
macrophages and monocytes .......................................................................................... 43 
3.3.2 Gene expression of M1 and M2 markers in M-CSF and L-428 CM derived 
macrophages .................................................................................................................. 47 
3.3.3 Transcriptional changes in L-428 CM derived macrophages compared to M-CSF 
and HBL-1 CM derived cells ........................................................................................... 49 
3.4 Functional properties of L-428 CM and M-CSF derived macrophages ....................... 51 
VIII 
 
3.4.1 L-428 CM and M-CSF differentiated macrophages can be repolarized toward 
the M1 type .................................................................................................................... 51 
3.4.2 Endocytosis of specific targets is enhanced in L-428 CM macrophages .............. 53 
3.4.3 Collagen uptake is enhanced in L-428 CM derived macrophages and 
macrophages secret high amounts of MMP-9 .................................................................. 55 
3.4.4 Co-culture of L-428 cells and macrophages in an in vivo chorion allantois 
membrane assay leads to altered tumor formation ......................................................... 56 
3.5 CD206 expression on L-428 CM derived macrophages ............................................. 58 
3.5.1 IL-13 induces gene and cell surface expression of CD206 ................................. 58 
3.5.2 MRC1 expression is abolished in monocytes treated with JAK inhibitors ........... 60 
3.5.3 CD206 expression after stimulation with cHL and DLBCL CMs ......................... 61 
3.6 Recruitment of macrophages and repolarization by lymphoma secreted factors ....... 63 
4 Discussion ...................................................................................................................... 65 
4.1 Recruitment and differentiation of macrophages by lymphoma secreted factors ...... 65 
4.1.1 Recruitment of monocytes and macrophages by chemoattractants in 
lymphoma CM ................................................................................................................ 65 
4.1.2 Differentiation of monocytes into macrophages by lymphoma derived factors .. 67 
4.2 Phenotype and functions of cHL recruited macrophages .......................................... 68 
4.2.1 Expression of cell surface markers and functional implications ......................... 68 
4.2.2 CD206 expression and endocytic activity of cHL CM derived macrophages ....... 70 
4.3 Factors inducing CD206 expression on cHL derived macrophages ........................... 71 
5 Summary and Conclusion ............................................................................................... 73 
References ............................................................................................................................. 74 
Appendix ............................................................................................................................... 90 





List of figures 
Figure 1: TAM mediated functions in the TME. ....................................................................... 6 
Figure 2: Structural properties of CD206. ................................................................................ 8 
Figure 3: Monocytes migrate toward cHL CM. ....................................................................... 40 
Figure 4: Differentiation of monocytes with various lymphoma CMs leads to differential 
outcome in cell numbers. ...................................................................................................... 41 
Figure 5: Gene expression of CSF1 and CSF2 and M-CSF secretion is most prominent in cHL 
cell lines. ............................................................................................................................... 42 
Figure 6: L-428 CM differentiated macrophages are smaller in forward and sideward scatter 
compared to M-CSF cells. ...................................................................................................... 44 
Figure 7: Surface expression of selected proteins in M-CSF or L-428 CM derived macrophages 
and freshly isolated monocytes. ............................................................................................. 46 
Figure 8: Gene expression of selected markers shows no differences between M-CSF and 
L-428 CM derived macrophages. ........................................................................................... 48 
Figure 9: Global gene expression analysis reveals upregulation of genes in L-428 CM derived 
macrophages involved in leukocyte activation, antigen presentation and endocytosis. ........... 50 
Figure 10: M-CSF and L-428 CM differentiated macrophages can be activated toward the 
M1 type. ................................................................................................................................ 52 
Figure 11: No differences in the uptake of polar beads between M-CSF and L-428 CM derived 
macrophages. ........................................................................................................................ 53 
Figure 12: Uptake of FITC-dextran is enhanced in L-428 CM derived macrophages compared 
to M-CSF cells. ...................................................................................................................... 54 
Figure 13: Collagen uptake is enhanced in L-428 CM derived macrophages and macrophages 
secret high amounts of MMP-9. ............................................................................................. 56 
Figure 14: Addition of macrophages alters tumor formation of L-428 cells in an in vivo CAM 
assay. .................................................................................................................................... 57 
Figure 15: CD206 gene and surface expression is induced by IL-13 and L-428 CM. ................ 59 
Figure 16: Inhibition of JAKs prohibits MRC1 expression in monocytes. ................................. 61 
Figure 17: Monocytes increase CD206 gene and surface expression after stimulation with 
cHL CM. ................................................................................................................................ 62 
Figure 18: Macrophages migrate toward lymphoma CM and increase CD206 gene expression 
after stimulation with cHL CM. .............................................................................................. 64 
X 
 
Figure A-19: Expression of selected cytokines and chemokines in L-428 and HBL-1 cells by 
RNA-seq. ............................................................................................................................... 90 
Figure A-20: Heatmap of differentially expressed genes between L-428 CM, M-CSF and 
HBL-1 CM derived macrophages. ........................................................................................... 91 
Figure A-21: GO term enrichment clusters calculated by DAVID for differentially expressed 
genes between L-428 CM and M-CSF derived macrophages. .................................................. 92 
Figure A-22: GO term and InterPro enrichment clusters calculated by DAVID for differentially 






List of tables 
Table 1: Cell lines .................................................................................................................. 15 
Table 2: Chemicals and solutions .......................................................................................... 15 
Table 3: Consumables ........................................................................................................... 18 
Table 4: Recipes of buffers and solutions ............................................................................... 19 
Table 5: Equipment ............................................................................................................... 21 
Table 6: Stimulants ............................................................................................................... 23 
Table 7: Inhibitors ................................................................................................................. 23 
Table 8: Antibodies for flow cytometry .................................................................................. 23 
Table 9: Antibodies used for immunohistochemical staining .................................................. 24 
Table 10: Oligonucleotides .................................................................................................... 25 
Table 11: Ready to use reaction systems ................................................................................ 25 
Table 12: Software ................................................................................................................ 26 
Table 13: Dehydration of CAM tumors .................................................................................. 32 
Table 14: Hemorrhage score for CAM tumors ........................................................................ 33 
Table 15: Dewaxing of CAM tumor sections .......................................................................... 34 
Table 16: Dehydration of stained CAM tumor sections .......................................................... 34 
Table 17: Trichrome staining of CAM tumor sections............................................................. 34 
Table 18: Peroxidase staining of CAM tumor sections ............................................................ 35 
Table 19: Reverse transcription mastermix ............................................................................ 36 
Table 20: Reverse transcription cycler program ..................................................................... 36 








ABVD chemotherapy regimen of doxorubicin, bleomycin, vinblastine, and 
dacarbazine 
ADAM a disintegrin and metalloproteinase 
Arg1 arginase 1 
APC allophycocyanin 
BAFF B cell activating factor 
BEACOPP chemotherapy regimen of bleomycin, etoposide, doxorubicin, 
cyclophosphamide, vincristine, procarbazine and prednisone 
bFGF basic fibroblast growth factor 
CAM chorion allantois membrane 
CCL chemokine (C-C motif) ligand 
CCR chemokine (C-C motif) receptor 
CD cluster of differentiation 
CD1a+ CD1a positive (cell) 
CD4+ CD4 positive (cell) 
CD8+ CD8 positive (cell) 
CD14+ CD14 positive (cell) 
CD206+ CD206 positive (cell) 
cHL classical Hodgkin lymphoma 
CLEC C-type lectin-like domain containing protein 
CM conditioned medium 
CR cysteine-rich (domain) 
CTLD C-type lectin-like domain 
ctrl control 
CX3CL1 chemokine (C-X3-C motif) ligand 1 
CX3CR1 chemokine (C-X3-C motif) receptor 1 
CXCL chemokine (C-X-C motif) ligand 
DC dendritic cell 
DLBCL diffuse large B cell lymphoma 
EMT epithelial to mesenchymal transition 
FCS fetal calf serum 
XIII 
 
FcγR Fcγ receptor 
FITC fluorescein isothiocyanate 
FNII fibronectin type II (domain) 
fwd forward 
GalNAc N-acetylgalactosamine  
GlcNAc N-acetylglucosamine  
GM-CSF granulocyte-macrophage colony-stimulating factor 
HL Hodgkin lymphoma 
HLA human leukocyte antigen 
HRS Hodgkin-Reed-Sternberg (cell) 
IFN-γ interferon-γ 
IL interleukin 
iNOS inducible nitric oxide synthase 
JAK Janus kinase 
KO knock out 
M-CSF macrophage colony-stimulating factor  
M-CSF-R macrophage colony-stimulating factor receptor 
MHC major histocompatibility complex  
MICA MHC class I polypeptide-related sequence A  
MMP matrix metalloproteinase 
NK natural killer (cell) 
NKG2D natural killer group 2D  
NLPHL nodular lymphocyte-predominant Hodgkin lymphoma 
OS overall survival 
PD-1 programmed cell death protein 1 
PD-L1 programmed cell death 1 ligand 1 
PE phycoerythrin 
PFS progression free survival 
PLA2 phospholipase A2 
PLA2R phospholipase A2 receptor  
PPARγ peroxisome proliferator-activated receptor γ 




RNA-Seq RNA sequencing 
SAA3 serum amyloid A3 
STAT signal transducer and activator of transcription 
TAM tumor associated macrophage 
TGF-β transforming growth factor β 
TH T helper (cell) 
TME tumor microenvironment 
TNF-α tumor necrosis factor α 
TReg regulatory T cell 
TYK2 tyrosine kinase 2 
uPAR urokinase-type plasminogen activator receptor  
VEGF vascular endothelial growth factor  
 
 Introduction 
   1 
 
1 Introduction 
For several decades tumor research was mainly based on identifying the genetically aberrant, 
malignant cells and their tumorigenic potential. However, in the past twenty years the view 
has shifted from cancer being a collection of mutated cells toward a systemic understanding of 
the disease. Otherwise healthy but malfunctioning cells built up a complex structure with the 
malignant cells to support tumor establishment, growth and progression. Together with 
extracellular matrix and soluble factors this is referred to as the tumor microenvironment 
(TME) (Egeblad et al. 2010). 
The TME plays an active role in tumor development generally by providing a tumor supportive 
milieu thereby promoting tumor growth and progression (Wang et al. 2017). The cellular 
components consist of a variety of immune cell infiltrates such as T cells, B cells, natural killer 
(NK) cells, neutrophils, mast cells, dendritic cells (DC) and macrophages (Kerkar & Restifo 
2012). Under physiological conditions the immune system provides an anti-tumor response to 
genetically and phenotypically aberrant cells, however, within the TME the cells are 
functionally defect. The immune cells are unable to act against the malignant cells either due 
to exhaustion or because they are manipulated to actively support cancer cells by suppressing 
immune responses or by supplying growth factors and other stimulants (Albini et al. 2015; 
Pauken & Wherry 2015). Beside the cellular compartment also extracellular matrix 
components are altered in the tumor tissue and themselves possess tumorigenic properties 
(Wang et al. 2017; Afik et al. 2016). The composition of soluble factors is partly a result of the 
neoplastic cells secretome as well as of the recruited benign cells. Taken together these factors 
form with the neoplastic cells a complex structure that in its whole built up the tumor 
(Egeblad et al. 2010). More recent clinical studies have focused on the TME and found that 
the composition of the TME is connected to disease progression, prognosis and influence 
treatment response (Pagès et al. 2010). Hence, analysis of TME-cancer cell interactions have 
increased rapidly in the last two decades to reveal mechanisms by which cancer cells establish 
their own immune suppressive and tumor promoting structures and how to address this 
therapeutically. 
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1.1 Macrophages 
Macrophages have been found in tumors of literally every origin and localization. Commonly 
their presence has been associated with poor prognosis, early relapse and treatment failure 
(Shabo et al. 2008; Atanasov et al. 2015; Steidl et al. 2010; Deau et al. 2013). 
Macrophages are part of the innate immune system and characterized by professional 
phagocytosis (Cavaillon 2011). They are common in all tissues and play an important role in 
tissue homeostasis by patrolling the environment for foreign cells and particles or damaged 
and dead body cells. Upon encountering potential pathogens macrophages can promote an 
inflammatory response whereas the clearance of apoptotic cells requires immune suppression 
to allow tissue regeneration. Thus, they also have the ability to dampen inflammatory 
reactions. Because of their ability to fulfill these opposing functions alongside with the ability 
to encourage tissue repair and wound healing macrophages are viewed as key regulators in 
the immune system which has become of special interest in the context of the TME. 
1.1.1 Macrophage origin and development 
Macrophages are present throughout the body in relatively constant numbers. The first known 
route of macrophage to occur was by differentiation from monocytes. Monocytes recruited 
from the blood stream into a tissue can further develop into macrophages (Varol et al. 2009). 
However, it was later found that the pool of tissue resident macrophages does not require 
per se monocyte recruitment. Analysis of knock out (KO) mice where differentiation of 
monocytes to macrophages was inhibited showed that the number of macrophages are stable 
in healthy individuals and not reduced compared to wild type mice (Bigley et al. 2011). 
Consequently, it was also shown that tissue resident macrophages can maintain themselves by 
self-renewal and that colonization of the body during embryogenesis does not require 
monocytes (Ajami et al. 2007; Aziz et al. 2009; Schulz et al. 2012). Macrophages colonize the 
body in two waves during embryogenic development which has been studied in detail in mice. 
They first appear during yolk sac hematopoiesis at day 7 of development (Palis et al. 1999). 
Myeloid progenitor cells differentiate directly into macrophages which spread from the yolk 
sac into the body. The second wave occurs during fetal liver hematopoiesis at day 10. In this 
stage fetal monocytes disseminate from the fetal liver into the body and further differentiate in 
the tissues to macrophages (Naito et al. 1990; Hoeffel et al. 2012). Thus, most tissue 
macrophages originate prior to birth. The tissue resident macrophages were shown to be 
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self-renewal, hence, recruitment from monocytes is not required. However, if recruitment or 
recolonization is necessary for example during or after infections, macrophages can be derived 
from circulating monocytes that originate from the bone marrow. 
Upon colonizing of a tissue or encountering changes within their tissue macrophages adapt 
their phenotype accordingly. As a result of multiple surrounding factors, such as soluble 
molecules, direct cell-cell interactions as well as chemical and physical properties of the 
extracellular matrix macrophages change their state, hence, giving rise to multiple tissue 
specific phenotypes (Varol et al. 2015). It has been shown that this specification is not an end 
point and cells can adapt their phenotype further in response to changes in their environment. 
One example for changes in the microenvironment can be the infiltration of pathogens. 
Macrophages are able to detect foreign material in the tissue and in such a case they will get 
activated toward a so called M1 type and induce an immune reaction. 
1.1.2 Macrophage activation: The M1-M2 axis 
Due to their high plasticity that is maintained throughout their lifespan macrophages are not 
classified into subtypes. Since they commonly show similar phenotypes within a specific niche 
macrophages can be categorized by their localization (section 1.1.1) but more common is the 
description of the activational state. Roughly, macrophages promoting immune responses as a 
result of danger signals are referred to as M1 activated whereas cells suppressing immune 
actions to support wound healing are referred to as M2 activated (Mills et al. 2000; Gordon 
2003). The nomenclature comes from their function in this context to promote T cells to either 
produce T helper (TH) 1 cytokines or TH2 cytokines which in turn activate more macrophages 
toward an M1 or M2 type, respectively. In mice it was found that M1 macrophages preferably 
produce inducible nitric oxide synthase (iNOS) to generate NO from arginine. The NO is 
further metabolized to reactive nitrogen species leading to an oxidative burst and elimination 
of invading microorganisms. M2 cells were found to produce ornithine from arginine by 
arginase 1 (Arg1) which is the substrate for polyamine and proline syntheses, important 
molecules for cellular proliferation and tissue repair (Mills & Ley 2014). This clear distinction 
of macrophage activation by arginine metabolism, however, seems to be invalid in humans 
(Weinberg et al. 1995; Raes et al. 2005; Martinez et al. 2006). In in vitro studies usually a 
panel of surface markers and secreted cytokines is analyzed to determine the activation state. 
These include tumor necrosis factor (TNF)-α, interleukin (IL)-12, IL-23, chemokine (C-C 
Motif) receptor (CCR)7 and cluster of differentiation (CD)40 for M1 activated cells and 
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CD163, CD206, chemokine (C-C Motif) ligand (CCL)17, CCL18 and transforming growth 
factor (TGF)-β for M2 activated cells (Murray et al. 2014). In histological analysis of tumor 
sections the presence of M2 macrophages is usually demonstrated by staining of CD163 or 
CD206. To distinguish M1 activation transcription factors such as phosphorylated signal 
transducer and activator of transcription 1 (pSTAT1) and recombining binding protein 
suppressor of hairless (RBP-J) are used (Barros et al. 2013). Detailed analysis of macrophage 
phenotypes, however, revealed that they possess a broader activation spectrum than initially 
defined by the M1-M2 dichotomy. Comprehensive transcriptome analysis of responses toward 
different stimuli and stimuli combinations showed that several M1- and M2-like state exist that 
are not detected by previously defined markers (Xue et al. 2014). Broadly it has been 
concluded from this and other studies that rather than an M1-M2 axis with roughly opposing 
states there is a whole landscape of activation states macrophages can switch to (Mosser & 
Edwards 2008). Reconstruction of the macrophage polarizations in the TME have supported 
this view (Kiss et al. 2018). 
1.1.3 Tumor associated macrophages 
Macrophages are referred to as tumor associated when they reside within or in close proximity 
to the tumor. Macrophages are common in all tissue and can regulate immune reaction and 
tissue homeostasis. Almost consequently macrophages can be found within tumors of any 
origin and localization. Analyses across different entities showed that the percentage of 
macrophages usually ranges from 5 % to 50 % (Gentles et al. 2015). According to the 
classification into activational states tumor associated macrophages (TAM) roughly resemble 
M2 macrophages or are described as M2-like as they are often detected by CD163 or CD206 
expression in tumor sections (Heusinkveld & van der Burg 2011; Zhang et al. 2012). Using 
these markers, however, leads to a bias since they are characteristic for M2 activated cells.  
Analysis of intratumoral macrophages by single cell RNA sequencing or mass spectrometry 
revealed a high heterogeneity in this population with phenotypes that are not covered by the 
bimodal description of M1-M2 activation (Chevrier et al. 2017; Lavin et al. 2017). This 
suggests a highly dynamic regulation of macrophages in the TME. Since in vitro generated 
cells normally do not show the same degree of heterogeneity the functional relevance of these 
subsets and thereby the whole regulatory potential of TAMs remain unclear. 
Irrespective of their specific phenotype within the tumor macrophages have been shown to 
fulfill several pro-tumoral functions e.g. by promoting angiogenesis, encouraging metastasis 
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and preventing immune responses best described by suppressing cytotoxic T cell activity 
(Figure 1). Studies found that TAMs promote angiogenesis by secretion of vascular endothelial 
growth factor (VEGF), tumor necrosis factor α (TNF-α), IL-1β, IL-8, and basic fibroblast growth 
factor (bFGF) (Mantovani et al. 2002; De Palma & Lewis 2013). Besides by secretion of matrix 
metalloproteinases (MMP) and other matrix modulating enzymes such as urokinase-type 
plasminogen activator receptor (uPAR) they can promote vessel formation (Coussens et al. 
2000; Hildenbrand et al. 1999). Correlation studies have furthermore shown that the 
macrophage content is linked to the microvessel density supporting the view that TAMs expose 
pro-angiogenic functions (Badawi et al. 2015; Zhang et al. 2011). Aside from promoting 
angiogenesis the matrix remodeling activity of macrophages supports metastasis. TAMs are a 
major source of proteolytic enzymes apart from MMPs these include e.g. cathepsins and a 
disintegrin and metalloproteinases (ADAM) which accounts for matrix degradation in the TME 
(Mason & Joyce 2011). The altered stroma architecture leads to enhanced tumor cell invasion 
and metastasis by removing the physical barriers but also by releasing growth factors stored in 
the extracellular matrix (Liguori et al. 2011). Metastasis is furthermore promoted by 
macrophages present in the premetastatic niches. These macrophages have been primed by 
tumor cell derived factors, e.g. tumor exosomes, or by TAM derived factors such as serum 
amyloid A3 (SAA3) and TNF-α and supported extravasation, establishment and growth of the 
tumor cells which was observed in mouse models of melanoma and lung metastasis (Peinado 
et al. 2012; Tomita et al. 2011; Qian et al. 2009). An important aspect in promoting 
metastasis in solid cancers is that macrophages can support the epithelial to mesenchymal 
transition (EMT) e.g. by secretion of transforming growth factor β (TGF-β) which is a critical 
step for neoplastic epithelial cells to gain migratory and invasive properties (Gao et al. 2012). 
Another well described and important function of TAMs is the establishment of an immune 
suppressive environment among other mechanisms by inhibiting the cytotoxic activity of 
T cells. One example is the expression of programmed cell death protein 1 ligand 1 (PD-L1) on 
their cell surface and the direct interaction with T cells expressing the inhibitory receptor 
programmed cell death protein 1 (PD-1) (Carey et al. 2017). Additionally, they can carry other 
co-inhibitory ligands such as B7-H4 or secrete immune suppressive stimuli such as IL-10 
(Kryczek et al. 2006; Ruffell et al. 2014). Aside from direct interaction TAMs can recruit 
regulatory T cells (TReg) through the secretion of CCL17 and CCL22, which in turn mediate the 
inhibition of cytotoxic T cells (Kryczek et al. 2006). 
 Introduction 
   6 
 
 
Figure 1: TAM mediated functions in the TME. 
TAMs can promote angiogenesis and metastasis, regulate matrix organization and suppress immune responses. 
Mediating factors are depicted next to each function, references are given in the text (section 1.1.3). 
 
The clinical relevance of TAMs has long been discussed. There are now various studies that 
have correlated the frequency of TAMs with a poor overall survival (OS) or progression free 
survival (PFS). On the contrary there are also a notable numbers of reports that have found no 
such correlation (Heusinkveld & van der Burg 2011; Kridel et al. 2015; Guo et al. 2016). It has 
to be noted that detection methods and the applied thresholds for macrophage contents vary 
broadly between different studies. However, the increasing number of reports that have found 
a negative correlation of OS and PFS with the amount of macrophages present in the tumor is 
indicating that macrophages indeed might play an important role in tumor progression but the 
prognostic impact is still controversial. Aside from the prognostic value there is evidence that 
macrophages can modulate the outcome of anti-cancer therapy. In mice experiments it was 
shown that macrophages interfere with chemo- and radiotherapy. In a mouse model of 
prostate cancer macrophages were recruited to the tumor site shortly after radiotherapy to 
stimulate tumor regrowth (Xu et al. 2013). Additionally, macrophages were mobilized to the 
tumor site in breast cancer models after applying chemotherapeutic agents and protected 
cancer cells from chemotherapeutic induced death (DeNardo et al. 2011; Shree et al. 2011). 
Macrophages can also interfere with antibody based therapies via their Fcγ receptors (FcγR). 
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cytotoxicity or phagocytosis in macrophages thereby enhancing the efficiency of antibody 
therapies (Clynes et al. 2000; Minard-Colin et al. 2008). However, it was also shown that 
immunosuppressive, pro-angiogenic, and pro-tumoral effector functions can be activated upon 
FcγR-antibody binding (Grugan et al. 2012; Andreu et al. 2010; Pander et al. 2011). Another, 
therapeutically exploitable functional aspect of TAMs is their immune suppressive behavior 
especially the inhibition of cytotoxic CD8+ T cells. Hence, depletion of macrophages to allow 
anti-tumor T cell cytotoxicity was introduced as a new therapeutic strategy. A study in cervical 
cancer showed that depletion of macrophages enhanced infiltration of CD8+ T cells (Lepique 
et al. 2009). However, macrophage depletion might lead to compensatory effects such as 
recruitment of granulocytes to the tumor site as seen in a mouse model of melanoma (Kumar 
et al. 2017). Another idea is to reprogram macrophages toward a M1 phenotype which then 
expose anti-tumor activity or activate T cells. This has been shown a promising approach in 
bladder cancer and pancreatic cancer models (Beatty et al. 2011; Luo & Knudson 2010). 
In conclusion, macrophages exhibit a plethora of phenotypes and functions. This includes 
angiogenesis, metastasis, immune suppression and interference with antitumor treatments. 
The recent findings on macrophage behavior in the TME have led to a variety of new 
therapeutic strategies. However, there is still the need to learn more about the mechanism of 
their manipulation and their actions especially in context of treatment strategies to fully 
exploit their potential in therapeutic concepts. 
 
1.2 The mannose receptor CD206 
The mannose receptor, also known as CD206 or macrophage mannose receptor, is a C-type 
lectin and part and eponym of the mannose receptor family. These receptors are described as 
being involved in the endocytosis of exogenous and endogenous substrates accounting for 
functions in host defense and tissue remodeling. Clinically CD206 became relevant as a marker 
for M2 activated macrophages in the TME. 
1.2.1 The mannose receptor family 
The mannose receptor family is a family of structurally related proteins consisting of four 
members in mammals, i.e. mannose receptor (CD206), Endo180 (CD280), phospholipase A2 
receptor (PLA2R) and Dec-205 (CD205). Each family member is built up by five elements: a 
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short C-terminal cytoplasmic domain, a transmembrane region, 8-10 C-type lectin-like 
domains (CTLD), a fibronectin type II domain (FNII) and N-terminal a cysteine-rich (CR) 
domain (see Figure 2 for the structure of CD206). The cytoplasmic tail of the proteins has no 
known functions while the transmembrane domain anchors the protein in the cell membrane. 
The three extracellular domains can bind to specific targets and mediate their internalization.  
 
Figure 2: Structural properties of CD206. 
Schematic of the structure of CD206 in an extended conformation. CTLD (red), FN II (yellow) and CR (green) 
domains are shown. CTLD4 (dark red) mediates sugar binding. Ligands of each domain are given in the 
corresponding color (Man–mannose, Fuc–fucose, Gal–galactose) (Taylor et al. 2005). 
 
The CTLDs bind to terminal mannose, fucose and N-acetylglucosamine (GlcNAc) residues, the 
FNII domain was shown to bind collagens and the CR domain binds to sulfated galactose and 
sulfated N-acetylgalactosamine (GalNAc) (Fiete et al. 1998; Martinez-Pomares et al. 2006). 
Not all domains have been shown to be functional in each protein. The binding of residual 
mannose, fucose and GlcNAc is mediated by only one CTLD, this is CTLD4 in CD206, CTLD2 
in Endo180 and CTLD5 in PLA2R (Llorca 2008). For DEC-205 no carbohydrate binding was 
demonstrated so far. The FNII domain has been shown to bind collagens in all protein family 
members, however, with varying affinity to different collagen types (Martinez-Pomares 2012). 
The CR domain has only been shown to be functional in CD206 (Leteux et al. 2000). Despite 
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proteins. Analysis of the structure revealed that proteins of this family can either exist in an 
elongated or bent form (Napper et al. 2001; Boskovic et al. 2006). In this bent conformation 
the sugar binding CTLD and the collagen binding FNII domain come into close proximity 
which might account for ligand specificity of the receptors (Llorca 2008). Additionally, 
multimerization is required for the functioning of the receptors. As it was shown for isolated 
CD206 and Endo180, these receptors are unable to bind collagen as monomers but substrate 
binding was seen after crosslinking (Martinez-Pomares et al. 2006). The substrate uptake is 
clathrin dependent (Howard & Isacke 2002; Martinez-Pomares 2012). After internalization 
into the early endosome the receptors can be retrieved and transported back to the cell 
membrane. Thus, the receptors cycle constantly between the plasma membrane and 
intracellular compartments, only about 15 % of the receptors are present at the cell surface 
(Howard & Isacke 2002; Taylor et al. 2005). 
1.2.2 Expression and functions of CD206 
CD206 is expressed by macrophages, DCs and endothelial cells. The tissue distribution is well 
studied in mouse and CD206 positive cells can be found in most tissues (Martinez-Pomares 
2012). Various exogenous and endogenous ligands have been described for the mannose 
receptor, implicating several functions of the receptor in inflammation and homeostasis. First 
descriptions of CD206 have placed it as a clearance system for circulating lysosomal 
hydrolases (Lee et al. 2002). In the following more endogenous substrates have been 
identified, e.g. lutropin, and cells expressing CD206 were shown to clear these substrates from 
the system (Leteux et al. 2000). Other endogenous molecules that can be bound and 
internalized by CD206 are collagens (Martinez-Pomares et al. 2006). The collagen uptake 
might indicate a role for the receptor in tissue reorganization such as during developmental 
processes. However, CD206 KO mice showed no disruption of tissue development (Martinez-
Pomares et al. 2006). Among the exogenous binding partners of CD206 are several microbes 
including bacterial pathogens such as Mycobacterium tuberculosis and fungi like Candida 
albicans (Lee et al. 2003). It is suggested that via binding to CD206 an enhanced phagocytosis 
and pathogen clearance is achieved. However, again in KO mice no inferior immune defense 
was observed after fungal infection (Swain et al. 2003; Lee et al. 2003). Therefore, the 
involvement of the receptor in inflammatory reactions remains unclear. It has to be considered 
that loss of CD206 might be compensated by upregulation of other mannose receptor family 
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members or other cell types resume CD206 mediated functions, e.g. fibroblasts expressing 
Endo180 (Martinez-Pomares et al. 2006; Bianchetti et al. 2012). 
In DCs it was shown that internalization of substrates via CD206 led to presentation of the 
according peptides and glycolipids in major histocompatibility complex (MHC) class II or 
CD1b molecules, respectively (Tan et al. 1997; Prigozy et al. 1997). This links the endocytic 
functions of the receptor to immune responses in inflammatory processes though direct 
contribution via pathogen uptake could not be proven. Interestingly, CD206 expressed on DCs 
can also bind directly to T cells via CD45. A study showed that this direct interaction in 
combination with antigen crosspresentation via MHC I reduced the cytotoxic activity of CD8+ 
T cells (Schuette et al. 2016). 
In conclusion, many possible ligands and mechanisms of action have been described for 
CD206 by in vitro studies. In infection the receptor might contribute to inflammatory 
responses by enhancing the antigen presentation of DCs. Besides through the direct DC-T cell 
interaction the receptor might play a role in immune tolerance. Whether these functions can 
be exhibited in macrophages remains unclear. For macrophages specifically it was shown that 
expression of the receptor by murine bone marrow resident cells mediated collagen uptake, 
thus, indicating a role aside from inflammatory reactions to tissue homeostasis or remodeling. 
However, fibroblasts were shown to fulfill the same function via Endo180. Taken together, the 
impact and relevance of the proposed functions found in vitro in physiological conditions still 
needs to be evaluated. 
 
1.3 Hodgkin lymphoma 
1.3.1 Clinical and molecular features of Hodgkin lymphoma 
Hodgkin lymphoma (HL) is a rare hematological malignancy. In Germany, HL accounts for 
14 % of lymphoma cases and an estimate of 2510 cases will be diagnosed in 2018. In nearly 
4 % of cases patients will be children (below 15 years) (Robert Koch-Institut, 2017). HL is 
categorizes into two main subgroups, the classical Hodgkin lymphoma (cHL), which represents 
about 95 % of cases, and the nodular lymphocyte-predominant HL (NLPHL). Based on 
histological features cHL is further divided into four subtypes: nodular sclerosis (60 %), mixed 
cellularity (30 %), lymphocyte-rich and lymphocyte-depleted subtype (Swerdlow et al. 2008).  
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The standard treatment in cHL is chemotherapy using a combination of doxorubicin, 
bleomycin, vinblastine and dacarbazine (ABVD) followed by radiation. Another common 
chemotherapy regimen includes BEACOPP (bleomycin, etoposide, doxorubicin, 
cyclophosphamide, vincristine, procarbazine and prednisone) (Engert 2016). The prognosis of 
cHL is relatively good with 80 % curation rate using this combinational approach of chemo- 
and radiation therapy. The remaining 20 % account for cases of relapsed or refractory disease. 
The standard regimens for these patients is high-dose chemotherapy followed by autologous 
stem cell transplant, which leads to a curation rate of about 50 % in these cases (Hoppe et al. 
2017) . Hence, there are about one fifth of cases which are not cured by standard therapy and 
initial treatment failure or relapsed disease is accompanied by a drop in prognosis. Besides 
patients that have been successfully treated can have long-term side effects as a result of 
chemotherapy that diminish their life quality. Especially patients treated with radiation 
therapy have an increased risk to develop secondary malignancies. Also cardiac diseases occur 
in about 15 % of patients within the first five years after treatment (Hoppe et al. 2017). Thus, 
improving the therapy of cHL aims toward a reduction of toxicities and better therapy options 
for patients with initial treatment failure or relapsed disease. 
The malignant cells in cHL consist of mononuclear Hodgkin and bi- or polynuclear 
Reed-Sternberg cells (HRS). The phenotype of HRS cells is highly variable and shows feature 
of several lymphatic and myeloid lineages such as expression of CD3, granzyme B, CD20, 
macrophage colony stimulating factor receptor (M-CSF-R) and CD15 while the common 
leukocyte marker CD45 is absent.  Present on all HRS cells is CD30, a receptor of activated B 
and T cells, which is also used for diagnosis of cHL (Schmitz et al. 2009). Similarly 
deregulated and non-lineage specific is the cytokine expression profile of HRS cells. A wide 
spectrum of TH cell cytokines can be expressed by HRS cells, such as the TH2 cytokines IL-2, 
IL-5, IL-6, IL-9, IL-10, IL-13, and TH1 cytokines IL-12 and interferon (IFN)-γ as well as other 
cytokines like IL-1, TGF-β, IL-7, IL-8 and B cell activating factor (BAFF) (Skinnider et al. 2002; 
Aldinucci et al. 2016). Because of this lineage diversity the origins of HRS cells were discussed 
for years until their B cell origin was clarified by the detection of clonal and somatically 
mutated immunoglobulin heavy- and light-chain gene rearrangements (Küppers et al. 1994; 
Kanzler et al. 1996; Marafioti et al. 2000). 
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1.3.2 The microenvironment of classical Hodgkin lymphoma 
Characteristic for cHL is the small portion of malignant cells in the tumor that is outnumbered 
by the vast and rich cellular fraction of the TME. The malignant cells only account for 0.2-2 % 
of the cellular compartment within the tumor mass. They are embedded in a complex 
environment of non-neoplastic cells mainly consisting of immune infiltrates. Predominant in 
the TME are T cells with the occurrence of NK cells, mast cells, neutrophils, eosinophils, DCs 
and macrophages (Aldinucci et al. 2016). The immune infiltrates establish a reactive 
background for the malignant cells and support tumor progression. The cells show no further 
anti-tumor activity which they expose under healthy conditions. Analysis on how exactly HRS 
cells escape immune surveillance in the inflammatory milieu and built up their environment 
has been studied for years identifying multiple mechanisms. A well described mechanism for 
immune escape is the downregulation of MHC I on HRS cells which is correlated with inferior 
prognosis (Reichel et al. 2015; Roemer, Advani, Redd, et al. 2016). However, the absence of 
self-molecules on cells normally leads to the activation of NK cells. Thus, further mechanisms 
for immune suppression are developed in cHL. It was shown that HRS cells secret factors that 
can shed MHC class I polypeptide-related sequence A (MICA) from their cell surface which is 
the ligand for natural killer group 2D (NKG2D) a signal of damaged cells to become destroyed 
by immune cells. The soluble ligand binds to its receptor on NK and CD8+ T cells leading to 
receptor internalization thereby disrupting the immune defense against abnormal cells (Chiu 
et al. 2018). Despite mechanisms of immune evasion exhibited by HRS cells themselves, 
immune suppression in cHL is also outsourced to CD4+ T cells such as TRegs as well as to mast 
cells and macrophages. In clinical studies it was found that especially CD4+ T cells or TRegs are 
associated with a worse prognosis whereas CD8+ cell count correlates with a better prognosis 
(Koreishi et al. 2010; Hollander et al. 2018; Alonso-Álvarez et al. 2017). Additionally, studies 
reported that mast cells and macrophages correlate with worse prognosis (Glimelius et al. 
2005; Canioni et al. 2009; Guo et al. 2016). This indicates that an environment of regulatory 
immune cells that can mediate the escape from immune surveillance is advantageous for 
disease progression. Accordingly, HRS cells were found to produce large amounts of CCL17 
which recruits CCR4 positive TRegs, CCL5 to attract mast cells and CCL2 which is detected by 
monocytes (Aldinucci et al. 2008; Fischer et al. 2003; Niens et al. 2008; Luciani et al. 1998). 
Additionally, the number of macrophages is correlated with the number TRegs which might 
indicate that environmental cells are involved in the recruitment of each other as well (Barros 
et al. 2012; Barros et al. 2015).  
 Introduction 
   13 
 
Another well-known direct mechanism of HRS cells to silence CD8+ T cells is the PD-1-PD-L1 
interaction. HRS cells have genetic aberrations in the CD274 (PD-L1) gene locus leading to an 
increased expression of the protein on the cell surface (Roemer et al. 2016; Green et al. 2010). 
Besides a recent study described that macrophages within the TME express PD-L1 as well and 
are surrounded by CD8+ T cell presumably to mediate PD-L1 dependent inhibition of T cell 
cytotoxic activity (Carey et al. 2017). In 2012 two agent targeting the PD-1-PD-L1 axis were 
approved in Europe for treatment of relapsed cHL, nivolumab, and pembrolizumab, both 
inhibitory antibodies of PD-1. 
In conclusion, cHL is cancer entity with the distinguished and unique feature of a rich and 
complex TME where the non-neoplastic cells outnumber the malignant cells. HRS cells and the 
TME exhibit several functions to suppress immune responses thereby allowing tumor 
progression. The findings of defective PD-L1 expression on HRS cells led to the approval of 
immune therapeutic agents for relapsed cHL. Thus, further studies on the interaction of HRS 
cells with the TME might prove valuable for new therapeutic options. 
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Aims of this study 
Mutual interactions of HRS cells with non-transformed cells of the TME are a hallmark of cHL. 
There is growing evidence that the presence of macrophages in cHL is associated with poor 
prognosis. Studies in other entities have revealed that macrophages are critical regulators of a 
tumor supporting, immune suppressive microenvironment. How tumor cells built up their 
environment and which factors contribute to the recruitment and manipulation of bystander 
cells is still under investigation. In cHL the mechanisms by which macrophages enter the 
tumor and the functions they fulfill are likewise not completely understood. 
Thus, in this study we aim to gain a deeper insight into how HRS cells reprogram monocytes 
and macrophages, thereby answering the following questions: 
1. Can monocytes or macrophages be recruited by lymphoma derived factors? 
2. Can monocytes be differentiated into macrophages by lymphoma derived factors? 
3. How does lymphoma derived factors shape the macrophage phenotype and functional 
properties? 
4. Which lymphoma derived factors are involved in the process of macrophage 
polarization? 
In order to answer these questions migration of primary human monocytes and monocyte 
derived macrophages toward lymphoma secreted factors was investigated. Furthermore, 
lymphoma conditioned medium (CM) was used to differentiate monocytes into macrophages. 
The macrophages were characterized concerning their gene expression and protein surface 
expression. Identifying high CD206 expression as a specific marker of cHL derived 
macrophages functional aspects of the cells were further analyzed using different endocytosis 
assays. Tumor formation of cHL cells with macrophages was additionally observed in a 
chorion allantois membrane (CAM) assay. Lastly, IL-13 and macrophage colony stimulating 
factor (M-CSF), factors produced by cHL CM, were analyzed for their effects on CD206 gene 
and surface expression in monocytes and macrophages. 
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2 Material and Methods 
2.1 Material, recipes and equipment 
2.1.1 Cell lines 
Cell lines used in the present study are listed in Table 1. 
Table 1: Cell lines 
Cell line Source Reference 
HBL-1 Diffuse Large B Cell Lymphoma (EBV-) (Nozawa et al, 1988) 
HDLM-2 Hodgkin Lymphoma (EBV-) (Drexler et al, 1986) 
KM-H2 Hodgkin Lymphoma (EBV-) (Kamesaki et al, 1986) 
L-1236 Hodgkin Lymphoma (EBV-) (Wolf et al, 1996) 
L-428 Hodgkin Lymphoma (EBV-) (Schaadt et al, 1979) 
L-540 Hodgkin Lymphoma (EBV-) (Diehl et al, 1981) 
OCI-LY3 Diffuse Large B Cell Lymphoma (EBV-) (Tweeddale et al, 1987) 
 
2.1.2 Primary material 
Outdated Fresh Frozen Plasma bags from donors with blood group AB+ were kindly provided 
by the Department of Transfusion Medicine, University Medical Center Göttingen. 
Cell enriched fractions of whole human blood, so called buffy coats, were as well obtained 
from the Department of Transfusion Medicine, University Medical Center Göttingen. 
2.1.3 Chemicals, solutions and consumable supplies 
Chemicals, solutions and consumables used for this study are presented in Table 2 and     
Table 3. 
Table 2: Chemicals and solutions 
Chemical or solution Manufacturer 
10x DPBS Sigma-Aldrich, Munich, D 
Accutase solution Capricorn scientific, Ebsdorfergrund, D 
Acetic acid Roth, Karlsruhe, D 
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Chemical or solution Manufacturer 
Acid fuchsin Sigma-Aldrich, Munich, D 
Acrylamide/bisacrylamide 30 % Roth, Karlsruhe, D 
Acrylamide/bisacrylamide 40 % BioRad, Munich, D 
Ammonium persulfate (APS) Sigma-Aldrich, Munich, D 
Biocoll separating solution Biochrom, Berlin, D 
Bovine serum albumin (BSA) Serva, Heidelberg, D 
Bromophenol blue Sigma-Aldrich, Munich, D 
Calcium chloride (CaCl2) Merck Millipore, Billerica, USA 
Chicken eggs Valo BioMedia GmbH, Osterholz-
Scharmbeck, D 
Collagen (type-I) Trevigen, Gaithersburg, USA 
Crystal violet Sigma-Aldrich, Munich, D 
Deoxyribonucleoside triphosphates (dATP, 
dCTP, dGTP, dTTP) 
PrimeTech LTD, Minsk, BY 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Munich, D 
DPBS pH 7.4 (cell culture grade) PAN-Biotech GmbH, Aidenbach, D 
Eosin Roth, Karlsruhe, D 
Ethanol (100 %) J.T. Baker, Deventer, NL 
Ethylenediaminetetraacetic acid (EDTA) Riedel-de Haën, Seelze, D 
Full Range Rainbow Molecular Weight 
Marker 
GE Healthcare, Munich, D 
Gelatin Merck KGaA, Darmstadt, D 
Glutaraldehyde Roth, Karlsruhe, D 
Glycerol Roth, Karlsruhe, D 
Glycine Roth, Karlsruhe, D 
Goat serum Sigma-Aldrich, Munich, D 
Hematoxylin Sigma-Aldrich, Munich, D 
HEPES Sigma-Aldrich, Munich, D 
Hot FIREpol DNA polymerase PrimeTech LTD, Minsk, BY 
Hydrochloric acid (HCl) 37 % Sigma-Aldrich, Munich, D 
Hydrogen peroxide (H2O2) Sigma-Aldrich, Munich, D 
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Chemical or solution Manufacturer 
Iron(III) chloride (FeCl3) Sigma-Aldrich, Munich, D 
Isopropanol Sigma-Aldrich, Munich, D 
Lightgreen SF Sigma-Aldrich, Munich, D 
Magnesium chloride (MgCl2) PrimeTech LTD, Minsk, BY 
Mannose Roth, Karlsruhe, D 
Matrigel BD Biosciences, Franklin Lakes, USA 
Mayer’s hemalum solution Roth, Karlsruhe, D 
Methanol 100 % (p.a.) J.T. Baker, Deventer, NL 
Orange G Sigma-Aldrich, Munich, D 
Paraffin Roth, Karlsruhe, D 
Paraformaldehyde Roth, Karlsruhe, D 
Penicillin-Streptomycin Lonza, Basel, CH 
Percoll GE Healthcare, Freiburg, D 
Phosphotungstic acid (H3PW12O40) Sigma-Aldrich, Munich, D 
Ponceau S Sigma-Aldrich, Munich, D 
Potassium dihydrogen phosphate (KH2PO4) Roth, Karlsruhe, D 
Roti-Histokitt II Roth, Karlsruhe, D 
RPMI-1640 with L-glutamine Lonza, Basel, CH 
RPMI-1640 with L-glutamine, no phenol red Thermo Fisher Scientific, Waltham, USA 
Sodium azide (NaN3) Sigma-Aldrich, Munich, D 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, Munich, D 
Sodium chloride (NaCl) Merck KGaA, Darmstadt, D 
Sodium dihydrogen phosphate (Na2HPO4) Roth, Karlsruhe, D 
Sodium dodecyl sulfate (SDS) Merck KGaA, Darmstadt, D 
Sodium phosphate dibasic (NaH2PO4) Sigma-Aldrich, Munich, D 
SYBR Green I Nucleic Acid Gel Stain Roche, Mannheim, D 
Trehalose Roth, Karlsruhe, D 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Munich, D 
Tris-base Sigma-Aldrich, Munich, D 
Tris HCL Sigma-Aldrich, Munich, D 
TritonX-100 Roth, Karlsruhe, D 
 Material and Methods 
   18 
 
Chemical or solution Manufacturer 
Trypan blue 0.4 % in PBS Life Technologies, Carlsbad, USA 
Trypsin/EDTA (cell culture grade) Biochrom AG, Berlin, D 
Xylol Roth, Karlsruhe, D 
 
Table 3: Consumables 
Consumable Manufacturer 
384-well clear optical reaction plate Applied Biosystems, Foster City, USA 
Cell culture flasks T25, T75, T175 Sarstedt, Nümbrecht, D 
Cell separation columns MS, LS Miltenyi Biotec, Bergisch Gladbach, D 
Cryo tubes Nunc, Wiesbaden, D 
DryEase Mini Cellophane Thermo Fisher Scientific, Waltham, USA 
Falcon tubes 15 ml, 50 ml Sarstedt, Nümbrecht, D 
Filter tips 10 µl, 100 µl, 200 µl, 1000 µl Starlab, Ahrensburg, D 
Filtropur S 0.45 Sarstedt, Nümbrecht, D 
Membranes 5 µm pores Neuroprobe Inc, Gaithersburg, USA 
Optical adhesive covers Applied Biosystems, Foster City, USA 
Pasteur pipettes Sarstedt, Nümbrecht, D 
Pipette tips (w/o filters) 20 µl, 100 µl,  
1000 µl 
Sarstedt, Nümbrecht, D 
Reaction tubes 0.5 ml, 1.5 ml, 2 ml Sarstedt, Nümbrecht, D 
Serological pipettes 5 ml, 10 ml, 25 ml Sarstedt, Nümbrecht, D 
Sterling nitrile powder-free examination 
gloves 
Kimberly-Clark, Zaventem, B 
Syringe 5 ml, 10 ml, 50 ml B. Braun Melsungen, Melsungen, D 
Tissue culture dish 6 cm, 10 cm Sarstedt, Nümbrecht, D 
Tissue culture plates 6 well, 12 well, 24 well Sarstedt, Nümbrecht, D 
VueLife FEP cell culture bag 32 ml, 72 ml CellGenix, Freiburg im Breisgau, D 
Round bottom falcon tubes 5 ml Becton Dickinson, Franklin Lakes, USA 
Cryo box Nunc, Wiesbaden, D 
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2.1.4 Buffers and media 
Recipes of buffers and media used in this study are listed in Table 4. If not otherwise indicated 
all buffers and solutions are on water basis. 
Table 4: Recipes of buffers and solutions 
Buffer or solution Recipe 
Acid fuchsin solution 0.06 % (w/v) Ponceau S 
 0.5 mM Acid fuchsin 
 0,18 % (v/v) Acetic acid 
Cell culture medium I (lymphoma cells and  RPMI 1640 with L-glutamine 
macrophages) 10 % (v/v) FCS 
 100 U/ml Penicillin 
 100 µg/ml Streptomycin 
Cell culture medium II (monocyte  RPMI 1640 no phenol red 
isolation) 10 % (v/v) FCS 
Collagen I solution (1 mg/ml, membrane DPBS 
coating) 0.89 mM Sodium bicarbonate 
 1 mg/ml Collagen I 
Crystal violet staining solution 25 % (v/v) Methanol 
 0.5 % (w/v) Crystal violet 
Destaining solution 40 % (v/v) Methanol 
 10 % (v/v) Acetic acid 
Development buffer 50 mM Tris Base 
 0,15 mM Sodium chloride 
 10 mM Calcium chloride 
 7,7 mM Sodium azide 
DPBS-EDTA DPBS 
 1 mM EDTA 
FACS buffer DPBS 
 10 % (v/v) human AB serum 
Fixation buffer 5 % (v/v) Glycerol 
 30 % (v/v) Methanol 
Freezing medium 90 % (v/v) FCS 
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Buffer or solution Recipe 
 10 % (v/v) DMSO 
Iso-osmotic percoll solution 23.13 ml Percoll 
 1.87 ml 10x DPBS 
Lightgreen solution 0.135 % (w/v) Lightgreen SF 
 0.18 % (v/v) Acetic acid 
MACS buffer DPBS 
 0.5 % (w/v) BSA 
 1 mM EDTA 
Percoll separation solution 23 ml Iso-osmotic percoll solution 
 27 ml RPMI-1640 
Phosphotungstic acid + Orange G 3.6 % (w/v) Phosphotungstic acid 
solution 1.8 % (w/v) Orange G 
qRT PCR Mastermix 5.76 µl SYBRGreenMix 
 5 µM forward primer 
 5 µM reverse primer 
 10 ng cDNA 
 ad 8 µl H2O 
Renaturation buffer 2.5 % Triton-X-100 
Running buffer 25 mM Tris-Base 
 192 mM Glycin 
 34.67 mM SDS 
Sample buffer 62.5 mM Tris HCL pH 6,8 
 4 % (w/v) SDS 
 25 % (v/v) Glycerol 
 0.01 % (w/v) Bromphenolblau 
Separation Gel Mix 375 mM Tris-base, pH 8.8 
 25 % (v/v) Acrylamide/Bis solution (40 %) 
 0.0004 % (w/v) APS 
 0.00125 % (v/v) TEMED 
 2 mg/ml gelatin 
Stacking Gel Mix 125 mM Tris Base pH 6.8 
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Buffer or solution Recipe 
 12.5 % (v/v) Acrylamide/Bis solution (30 %) 
 0.0004 % (w/v) APS 
 0.00125 % (v/v) TEMED 
Staining solution 0.5 % (w/v) Coomassie-Blue 
 40 % (v/v) Methanol 
 10 % (v/v) Acetic acid 
SYBRGreenMix 1 x PCR buffer 
 3 mM MgCl2 
 1:80.000 SYBRGreen 
 0.2 mM dNTP each 
 20 U/ml Hot FIREpol DNA polymerase 
 0.25 % (v/v) TritonX-100 
 0.5 mM Trehalose 
TE buffer 10 mM Tris-base, pH 9 
 1 mM EDTA 
Weigert’s iron hematoxylin solution Ethanol 
(solution A) 1 % (w/v) Hematoxylin 
Weigert’s iron hematoxylin solution 17.9 mM Iron(III) chloride 
(solution B) 2.5 % (w/v) Hydrochloric acid 
Weigert’s iron hematoxylin solution 50 % (v/v) Solution A 
(working solution) 50 % (v/v) Solution B 
 
2.1.5 Equipment 
The equipment used in this study is listed in Table 5. 
Table 5: Equipment 
Instrument Manufacturer 
ABI PRISM 7900HT Fast Real-time PCR 
System 
Thermo Fisher Scientific, Waltham, USA 
Accu-jet Brand, Hamburg, D 
Biofuge Pico, Primo R Heraeus Instruments, Hanau, D 
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Instrument Manufacturer 
Boyden chamber 48-Well Neuroprobe Inc, Gaithersburg, USA 
Centrifuge 5451D Eppendorf, Hamburg, D 
Consort E734 Power Supply Schütt Labortechnik, Göttingen, D 
FACS Canto II BD Biosciences, Franklin Lakes, USA 
Filter wiper Neuroprobe Inc, Gaithersburg, USA 
Hera freeze -80°C freezer Heraeus Instruments, Hanau, D 
IKA KS 260 shaker IKA, Staufen, D 
IKAMAG RCT magnetic stirrer IKA, Staufen, D 
Incubator Cytoperm Heraeus Instruments, Hanau, D 
Incudrive incubator Schütt Labortechnik, Göttingen, D 
Leica DM 5000B with camera: DFC290 Leica Microsystems GmbH, Wetzlar, D 
MACS MultiStand Miltenyi Biotec, Bergisch Gladbach, D 
Microcoolcentrifuge 1-15k Sigma, Munich, D 
Microflow Laminar Downflow Workstation: 
Telstar Bio-II-A 
Azbil Telstar Technologies, Terrassa, E 
MiniMACS Separator Miltenyi Biotec, Bergisch Gladbach, D 
Motic SMZ-161 with Moticam 3 Motic, Hong Kong, CHN 
Multifuge 3 L-R Heraeus Instruments, Hanau, D 
ND-1000 UV/Vis-Spectrophotometer Thermo Fisher Scientific, Waltham, USA 
Neubauer Counting Chamber Improved Lo Labor Optik, Friedrichsdorf, D 
Power Pac 300 Power Supply Bio-Rad, Munich, D 
QuadroMACS Separator Miltenyi Biotec, Bergisch Gladbach, D 
Tecan Infinite F50 Reader Tecan Group Ltd., Männedorf, CH 
Thermocycler T3000 Biometra, Göttingen, D 
Thermomixer Compact Eppendorf, Hamburg, D 
Vortex Genie 2 Schütt Labortechnik, Göttingen, D 
Water bath Köttermann Labortechnik, Hänigsen, D 
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2.1.6 Stimulants and inhibitors 
Cells were stimulated with recombinant proteins and fluorescently labeled substances using 
the concentrations given in Table 6. Inhibitors used for this study with their respective 
working concentrations are listed in Table 7. 
Table 6: Stimulants 
Stimulant Manufacturer Final concentration 
FITC-dextran, 10kDa, 70 kDa Sigma-Aldrich, Munich, D 1 mg/ml 
Gelatin, Oregon Green™ 488 
Conjugate 
Thermo Scientific, Waltham, 
USA 
5 µg/ml 
IFN-γ, recombinant human Peprotech, Hamburg, D 10 ng/ml 
IL-13, recombinant human Peprotech, Hamburg, D 10 ng/ml 
Latex beads, 1µm, Nile red, 
carboxylate modified 
Thermo Scientific, Waltham, 
USA 
5 beads per cells 
LPS, E. coli O55:B5 Sigma-Aldrich, Munich, D 100 ng/ml 
M-CSF, recombinant human Immunotools, Friesoythe, D 2.5 ng/ml 
 
Table 7: Inhibitors 
Inhibitor Target Manufacturer Final concentration 




Merck, Darmstadt, D 1 µM 
Ruxolitinib JAK1/2 Selleck Chemicals, Houston, USA 1 µM 
 
2.1.7 Antibodies 
Antibodies used for flow cytometry are presented in Table 8. Antibodies used for 
immunohistochemical staining of CAM tumors are listed in Table 9. 
Table 8: Antibodies for flow cytometry 
Antibody Label Clone Manufacturer 
mouse anti CD1a FITC HI149 Immunotools, Friesoythe, D 
mouse anti CD11b FITC LT11 Immunotools, Friesoythe, D 
mouse anti CD11c FITC BU15 Immunotools, Friesoythe, D 
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Antibody Label Clone Manufacturer 
mouse anti CD14 FITC M5E2 BD Biosciences, Franklin Lakes, USA 
mouse anti CD163 APC GHI/61 BioLegend, San Diego, USA 
mouse anti CD206 APC 15-2 BioLegend, San Diego, USA 
mouse anti CD31 FITC MEM-05 Immunotools, Friesoythe, D 
mouse anti CD33 FITC HIM3-4 Immunotools, Friesoythe, D 
mouse anti CD40 FITC HI40a Immunotools, Friesoythe, D 
mouse anti CD44 FITC MEM-85 Immunotools, Friesoythe, D 
mouse anti CD54 FITC 1H4 Immunotools, Friesoythe, D 
mouse anti CD68 PE Y1/82A BD Biosciences, Franklin Lakes, USA 
mouse anti CD80 FITC MEM-233 Immunotools, Friesoythe, D 
mouse anti CD86 FITC BU63 Immunotools, Friesoythe, D 
mouse anti HLA-DR FITC G46-6 BD Biosciences, Franklin Lakes, USA 
mouse anti PDL1 APC 29E.2A3 BioLegend, San Diego, USA 
mouse IgG1 FITC PPV-06 Immunotools, Friesoythe, D 
mouse IgG1 PE MOPC-21 BD Biosciences, Franklin Lakes, USA 
mouse IgG2a FITC G155-178 BD Biosciences, Franklin Lakes, USA 
mouse IgG2b APC MPC-11 BioLegend, San Diego, USA 
mouse IgG2b FITC PLRV219 Immunotools, Friesoythe, D 
mouse IgG2b PE 27-35 BD Biosciences, Franklin Lakes, USA 
 
Table 9: Antibodies used for immunohistochemical staining 
Antibody Clone Manufacturer 
mouse anti CD30 Ber-H2 Dako, Agilent, Santa Clara, USA 
mouse anti CD68 KP1 Dako, Agilent, Santa Clara, USA 
goat anti-mouse HRP polyclonal Dako, Agilent, Santa Clara, USA 
 
2.1.8 Oligonucleotides 
Oligonucleotides used as primers in quantitative Real Time PCR are listed in Table 10. 
Oligonucleotides were synthesized by IBA GmbH (Göttingen, D). 
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Table 10: Oligonucleotides 
Gene (protein name) Sequence 
CCR7 fwd: GGC TGG TCG TGT TGA CCT ATA TCT 
 rev: GGT ATC GGT CAT GGT CTT GAG C 
CSF1 (M-CSF) fwd: GGA GAC CTC GTG CCA AAT TA 
 rev: CGC ATG GTG TCC TCC ATT AT 
CSF2 (GM-CSF) fwd: CGG AAA CTT CCT GTG CAA CC 
 rev: TCT CAC TCC TGG ACT GGC TC 
CXCL8 (IL-8) fwd: GCA GAG GGT TGT GGA GAA GT 
 rev: TTT GCT TGA AGT TTC ACT GGC AT 
GAPDH fwd: CAG CCT CAA GAT CAT CAG CA 
 rev: CAT GAG TCC TTC CAC GAT ACC 
IL10 fwd: AAC CTG CCT AAC ATG CTT CGA G 
 rev: AAC AAG TTG TCC AGC TGA TCC TTC 
IL13 fwd: GAT TCT GCC CGC ACA AGGT 
 rev: GCC ACC TCG ATT TTG GTG TCT 
IL1B (IL-1β) fwd: CTC TGG GAT TCT CTT CAGC CAA 
 rev: AAG TCA TCC TCA TTG CCA CTG T 
IL32 fwd: CCT CTC TGA TGA CAT GAA GAA GCT G 
 rev: CTC TGC CAG GCT CGA CAT CA 
MRC1 (CD206) fwd: TGG AGT AAT ATT CAC TGT TCA TCC T 
 rev: AGG GTC CAT CTT CCT TGT GT 
TNF (TNFα) fwd: TCT CTA ATC AGC CCT CTG G 
 rev: CTA CAA CAT GGG CTA CAG G 
 
2.1.9 Ready to use reaction systems 
Ready to use reaction systems and kits used for this study are presented in Table 11. 
Table 11: Ready to use reaction systems 
Ready to use reaction system Manufacturer 
CD14 microbeads Miltenyi Biotec, Bergisch Gladbach, D 
Cytofix/Cytoperm Kit BD Biosciences, Franklin Lakes, USA 
DAB High contrast kit Nordic BioSite AB, Täby, S 
Human M-CSF Quantikine ELISA Kit R&D Systems, Minneapolis, USA 
Nucleo Spin RNA II Machery-Nagel, Düren, D 
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Ready to use reaction system Manufacturer 
SuperScript™ II Reverse Transcriptase Thermo Scientific, Waltham, USA 
 
2.1.10 Software 
The software used in this study is listed in Table 12. 
Table 12: Software 
Software Developer 
ABI 7900HT Sequence Detection Systems 
Ver. 2.4 
Thermo Fisher Scientific, Waltham, USA 
Adobe Illustrator CS6 Ver 16.0.3 Adobe Systems Inc. San José, USA 
FACSDiva™ BD Biosciences, Franklin Lakes, USA 
GraphPad Prism 7.03 GraphPad Software Inc., La Jolla, USA 
ImageJ software 1.45s National Institutes of Health, Bethesda, USA 
Leica Application Suite Ver 3.8.0 Leica Microsystems GmbH, Wetzlar, D 
Magellan for F50 7.0 Tecan Group Ltd., Männedorf, CH 
Mendeley Desktop Ver 1.15.2 Mendeley Ltd, London, UK 
Microsoft Office (Word, Excel, 
PowerPoint) 
Microsoft Corporation, Redmont, USA 
ND-1000 V3.8.1 Thermo Fisher Scientific, Waltham, USA 
RQ Manager Ver. 1.2.1 Thermo Fisher Scientific, Waltham, USA 
Servier Medical Art (licensed under a 
Creative Commons Attribution 3.0 
Unported License) 
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2.2 Cell biology 
2.2.1 Cell culture 
All cell lines used were cultivated in culture medium I and maintained at 37°C with 5 % CO2. 
The cells were counted using a Neubauer chamber after mixing the cell suspension with 0.4 % 
Trypan blue solution and split every 2 – 3 d to maintain a cell density of 0.5-1.5 Mio/ml. Cells 
were kept in culture for up to five weeks. 
For freezing cells were centrifuged 5 min at 121xg and the pellet was collected in freezing 
medium to yield a cell density of 5 Mio/ml. Each 1 ml was filled into Cryo tubes which were 
transferred to -80°C in a Cryobox ensuring constant cooling down with 1°C/min. After 24 h the 
Cryo tubes were placed in a -150°C freezer for long term storage. 
For generation of conditioned media (CM) cells were seeded out at 0.5 Mio/ml. After 48 h the 
cell suspensions were centrifuged for 5 min at 121xg and the supernatant was filtered using a 
0.45 µm sterile filter. The conditioned medium was kept at -20°C and thawed immediately 
before use. 
For RNA isolation cells were counted and centrifuged 5 min at 121xg, washed with PBS and 
centrifuged again. The supernatant was removed and the cell pellet was stored at -80°C until 
RNA isolation. For RNA Sequencing one tenth Drosophila melanogaster cells were added to the 
cells for external Spike-In (Feist 2016). 
2.2.2 Isolation of human monocytes via double gradient centrifugation 
Monocytes from cell enriched fractions of whole blood, so called buffy coats, were isolated by 
double gradient centrifugation for further differentiation to macrophages in cell culture bags 
or Teflon dishes (Menck et al. 2014). In brief, each 25 ml of human blood cell suspension from 
one buffy coat was mixed with 25 ml DPBS EDTA and centrifuged for 10 min at 1350xg 
without brake. The interphase containing leukocytes was collected and DPBS-EDTA was added 
to a total volume of 30 ml. The cell suspension was then carefully layered on top of 15 ml 
Biocoll separating solution and centrifuged 30 min at 400xg without brake. Again the 
interphase containing mononuclear cells as well as platelets was collected and pooled into one 
tube. The cells were washed twice adding 40 ml DPBS-EDTA, centrifuged at 300xg for 10 min 
without brake and removing the supernatant containing platelets. The cell pellet was finally 
resuspended in 20 ml cell culture medium II and layered on top of 25 ml Percoll separating 
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solution. The gradient was centrifuged 30 min at 550xg without brake. Due to the colloidal 
silica particles coated with polyvinylpyrrolidone in the Percoll lymphocytes sedimentate at the 
bottom of the tube whereas monocytes remain in the interphase (Feige et al. 1982). The 
interphase was collected, diluted with DPBS-EDTA to give a total volume of 50 ml and 
centrifuged at 400xg for 10 min. The monocyte pellet was resuspended in 20 ml RPMI 1640 
containing 10 % FCS and cells were counted in a Neubauer chamber mixing the cell 
suspension with 0.4 % Trypan blue solution. 
2.2.3 Isolation of human monocytes via magnetic cell separation 
Monocytes were isolated from buffy coats via magnetic cell separation (MACS) for stimulation 
and inhibition experiments and functional assays. In short, mononuclear cells from buffy coats 
were isolated by Biocoll gradient centrifugation as described in the previous section. The cells 
were counted and resuspended in MACS buffer according to the manufacturer’s instructions. 
Cells were labelled with CD14 microbeads and washed following the manufacturer’s 
instructions. Up to 70 Mio cells were applied on a MS column and up to 700 Mio cells on an 
LS column. The columns were prepared by placing them into the corresponding cell separator 
attached to a Multistand and rinsing them with MACS buffer as depicted in the instruction 
guidelines. The labeled cell suspension was applied onto the column. After complete passage 
the column was rinsed three times with MACS buffer and the cell were eluated in MACS buffer 
by pushing the plunger in the column as described in the instruction guidelines. To estimate 
the purity of CD14+ cells in the resulting cell suspension 100 µl were stained with a FITC 
labeled CD14 antibody and data was collected on a FACS Canto II flow cytometer with 
FACSDiva software. Gating on CD14 positive events isolated cells were used for further 
experiments when the portion of CD14+ monocytes was 95 % or higher. Cell numbers were 
determined using a Neubauer chamber mixing the cell suspension with 0.4 % Trypan blue 
solution. 
2.2.4 Differentiation of human monocytes to macrophages 
Monocytes isolated by double gradient centrifugation were differentiated into macrophages in 
fluorinated ethylene propylene (FEP) coated cell culture bags which allows the detachment of 
the cells after the differentiation period. Cell were differentiated for 7 d at 37°C and 5 % CO2 
either in cell culture medium I containing 2.5 ng/ml Macrophage colony-stimulating factor 
(M-CSF) or in lymphoma CM mixed in equal amounts with cell culture medium I. 
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1x106 cells/ml were filled into FEP coated cell culture bags, adequate volumes for each bag are 
listed in Table 3. After 7 d cell culture bags were removed from the incubator and placed on 
ice for 1 h. Cell were resuspended by pulling the bag with minimal pressure 5 times over the 
edge of a desk or board. The cell suspension was removed from the bag using a syringe and 
centrifuged at 400xg for 10 min. Cells were resuspended in 10 ml medium, counted and 
seeded according to the experimental set-up. After adherence of the cells, macrophages were 
washed twice with DPBS to remove non-differentiated cell and debris and immediately used 
for further experiments. 
For differentiation with IL-13 cells were added to a cell culture bag in cell culture medium I 
containing 10 ng/ml IL-13, 2.5 ng/ml M-CSF or both and maintained for 7 d. After 1 d and 7 d 
an aliquot was removed and used for flow cytometric analysis. 
For RNA sequencing (RNA-Seq) macrophages were differentiated as described above using 
L-428 and HBL-1 CM mixed in equal amounts with cell culture medium I or cell culture 
medium I containing 2.5 ng/ml M-CSF. After 7 d macrophages were extracted from the cell 
culture bag and plated on cell culture dishes. After 3 h the cells were washed and lysed. 
Lysates were stored at -80°C until RNA isolation. The experiment was performed with 
macrophages from three donors and in duplicates for each condition (L-428 CM, HBL-1 CM, 
M-CSF). 
2.2.5 Stimulation and inhibitor treatment of human monocytes 
Monocytes isolated by MACS were used for stimulation and inhibitor treatment. 2 Mio cells 
were seeded in 2 ml cell culture medium I in a 12-well plate or in 1 ml cell culture medium I 
and 1 ml CM was added. Stimulants were added according to Table 6. For inhibitor treatment 
2 Mio monocytes were seeded in 1 ml cell culture medium in a 12-well plate. Inhibitors were 
added at two-fold of the final concentration as given in Table 7, equal amount of DMSO were 
added to control cells. After 1 h 1 ml cell culture medium I and IL-13 or CM was added. 
After the indicated time points cells were harvested by transferring the suspension to a 2 ml 
reaction tube followed by centrifugation at 1000xg for 5 min. The supernatant was removed 
and cells were washed once with ice cold DPBS. After another centrifugation step the 
supernatant was removed and the collected cell pellet was kept at -80°C until RNA extraction. 
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2.2.6 Stimulation of macrophages 
Macrophages were extracted from cell culture bags and plated in 6-well plates with 
0.5 Mio cells/well. Cells were allowed to adhere for 3 h, washed twice with DPBS and 1 ml cell 
culture medium I was added. 1 ml cell culture medium or 1 ml cell culture medium containing 
5 ng/ml M-CSF or lymphoma CM was added und macrophages were incubated for 24 h. 
Afterwards cells were washed with DPBS and immediately lysed. Lysates were stored at -80°C 
until RNA extraction. 
2.2.7 Flow cytometry 
Expression of cell surface proteins was examined using flow cytometry. Monocytes were 
analyzed directly after MACS, macrophages were analyzed directly taken from cell culture 
bags. Cells were centrifuged and taken up in FACS buffer at a density of 10 Mio/ml. Each 
250,000 – 500,000 cells were given in round bottom tubes and antibodies or isotype controls 
given in Table 8 were added in appropriate amounts. For intracellular staining of CD68 cells 
were fixed and permeabilized using Cytofix/Cytoperm Kit according to the manufacturer 
instructions before adding CD68 or the isotype control. Cells were stained for 20 min on ice 
and then washed by adding 500 µl 2 % BSA in DPBS and removing the supernatant after 
centrifugation for 5 min at 400xg. Following another washing step using DPBS cells were 
resuspended in 300 µl DPBS. Data was collected on a FACS Canto II flow cytometer using 
FACSDiva software. After gating on living cells doublets were excluded by plotting the width 
against the area of the side scatter. Unstained cells were used to adjust the laser powers. For 
each sample data from 5,000 – 10,000 single cells were collected. Mean fluorescence 
intensities were calculated by FACSDiva software. Mean fluorescence intensity ratios were 
obtained dividing the mean fluorescence intensity of each antibody by their corresponding 
isotype control. 
2.2.8 Endocytosis assays 
Endocytosis assays were performed to estimate the uptake of particles, sugars and collagen by 
macrophages. 1 Mio macrophages were seeded in 6 cm cell culture dishes and allowed to sit 
over night. The next day cells were washed twice with DPBS and covered with 1 ml Medium. 
For each condition tested two dishes were prepare. 20 min before adding a labeled substance 
one dish was placed on ice as control for surface binding. Carboxylate modified beads were 
added as 5 Mio beads in 20 µl aqueous solution, FITC-dextran was added to give a final 
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concentration of 1 mg/ml and OG-gelatin was used in a final concentration of 5 µg/ml. For 
blocking of dextran uptake with mannose, mannose was added at 3 mg/ml 10 min before 
addition of dextran. For bead and dextran uptake macrophages were incubated 2 h, for 
OG-gelatin uptake 30 min. Afterwards cells were washed twice with DPBS and harvested with 
trypsin/EDTA solution. Cells were transferred to round bottom tubes and centrifuged at 400xg 
for 5 min. The supernatant was removed and cells were fixed in 2 % PFA in DPBS for 10 min 
on ice. Cells were centrifuged again to remove the PFA solution and taken up in 300 µl DPBS. 
Fluorescence intensities were measured on a FACS Canto II flow cytometer using FACSDiva 
software as described in the previous section. Mean fluorescence intensities of 37°C samples 
were normalized to their corresponding control incubated on ice. 
2.2.9 Migration and invasion assay 
The chemotactic potential of lymphoma CM for monocytes and macrophages was determined 
using a Boyden chamber with a 5 µm porous membrane. 
In short, monocytes were isolated via magnetic cell separation and resuspended in RPMI 1640. 
The chamber was prepared filling the lower wells with RPMI 1640 containing 1 % or 10 % FCS 
or lymphoma conditioned medium. The 5 µm membrane was applied covering the wells and 
the upper chamber was attached to the lower chamber. 50,000 monocytes were filled in each 
upper well and allowed to migrate for 2 h. Afterward the upper chamber and the membrane 
was removed from the lower part and 22 µl of each lower well was mixed with 10 µl 
0.4 % Trypan blue solution. Cells were counted using Neubauer chamber slide chips. Six wells 
per condition were used in each experiment. 
For invasion assays with macrophages 5 µm membranes were coated using 1 mg/ml collagen I 
solution. Macrophages were washed and harvested using Accutase solution. Cells were 
resuspended in RPMI 1640 and cell viability was determined by counting in a Neubauer 
chamber using 0.4 % Trypan blue solution. Cells with viability higher than 85 % were used for 
invasion assays. The lower wells of the Boyden chamber were filled with RPMI 1640 without 
additives or containing 10 % FCS or lymphoma CM. 50,000 macrophages were applied to the 
upper wells. After 4 h the chamber was disassembled and cells from the top of the membrane 
were removed using a filter wiper. Cells attached to the bottom of the membrane were fixed in 
ice cold methanol and stained in Crystal violet staining solution. Stained membranes were 
applied on microscope slides, covered with mounting medium and a coverslip. Three pictures 
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per well were taken using a Leica DM 5000B microscope with camera and cells were counted 
using ImageJ software. Numbers of migrated cells are given as mean of three pictures per well. 
Four to six wells per condition were used in each experiment. 
2.2.10 Chick chorion allantois membrane assay 
Chick chorion allantois membrane (CAM) assays were performed by Frederike von Bonin 
including sawing of the egg shells, cultivation of L-428 cells, cell inoculation, tumor harvest, 
fixation, trichrome and peroxidase staining. Generation of macrophages and the later 
evaluation including scoring of hemorrhages, measurement of the tumor area, assessment of 
the results, microscoping of stained slices and statistics have been performed by me. 
In brief, eggs were bred for 4 d at 37°C and 80 % humidity with regular movement every 
40 min. At day 4 of egg development a 0.75 cm2 squared window was cut into the egg shell 
above the embryo using a saw and sealed with adhesive tape. After incubation for additional 
7 d, at day 11 of embryonic development, the egg was removed from the incubator. The 
window was cut open and 2 Mio L-428 cells, 2 Mio L-428 cells and 1 Mio L-428 CM derived 
macrophages or 1 Mio L-428 CM derived macrophages in 20 µl Matrigel were applied on the 
CAM. The window was again closed with adhesive tape and the inoculated eggs were 
incubated another 4 d. At day 15 of embryonic development the tumors were harvested. The 
window was cut open and the tumor with surrounding CAM was cut out and transferred to 
DPBS. The tumors were photographed using a Motic SMZ-161 stereomicroscope with camera 
and fixed over night in 4 % PFA in DPBS. Afterwards the tumors were dehydrated following 
the steps given in Table 13. The tumors were embedded in paraffin and finally cut into 4 µm 
thick slices on a microtome and placed on microscopic slides for subsequent staining. 




1 1.5 h 60 % Ethanol 
2 1.5 h 75 % Ethanol 
2 1.5 h 96 % Ethanol 
2 1.5 h 100 % Ethanol 
2 1.5 h Xylol 
1 1.5 h Paraffin 
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2.2.10.1 Measurement of CAM tumor areas 
The area of CAM tumors was measured using ImageJ software by means of top side pictures of 
CAM tumors. The tumor area was defined using the polygon tool. Pictures of a defined 
distance were used to set the scale and consequently the area of the encircled region was 
calculated. 
2.2.10.2 Scoring hemorrhages in CAM tumors 
Hemorrhages were scored based on appearance, intensity and relative area covered as 
proposed by Linke 2016. In each criterion zero to three points were given leading to a 
maximum of nine points per tumor (Table 14). 
Table 14: Hemorrhage score for CAM tumors 
Criteria Example    
I Appearance of 
hemorrhages 
0: none 
1: small, sporadic 
2: big, sporadic 
3: big, converging 
 
0 1 2 3 







0 1 2 3 
III Area covered by 
hemorrhages 
0: none 
1: <20 % 
2: 20 – 50 % 
3: >50 % 
 
0 1 2 3 
 
2.2.10.3 Trichrome staining of CAM tumor sections 
Tumor sections placed on microscopic slides were dewaxed and stained as listed in Table 15 
and Table 17, respectively. Stained section were dehydrated (Table 16) starting with 90 % 
ethanol and mounted with Roti-Histokitt II. After drying slides were ready for microscopy 
using a Leica DM 5000B microscope with camera. 
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3 3 min Xylol 
2 3 min 100 % Ethanol 
1 3 min 96 % Ethanol 
1 3 min 80 % Ethanol 
1 3 min 70 % Ethanol 
1 3 min Distilled water 
 




1 3 min 50 % Ethanol 
1 3 min 70 % Ethanol 
1 3 min 90 % Ethanol 
2 3 min 100 % Ethanol 
3 3 min Xylol 
 
Table 17: Trichrome staining of CAM tumor sections 
Time Solution 
2 min Weigert’s hematoxylin working solution 
3 min Tap water 
9 min Acid fuchsin solution 
5 min 1 % Acetic acid in water 
1 min Phosphotungstic acid + Orange G solution 
1 min 1 % Acetic acid in water 
1 min Lightgreen solution 
5 min 1 % Acetic acid in water 
 
2.2.10.4 Peroxidase staining of CAM tumor sections 
Tumor sections were dewaxed following the procedure given in Table 15. The antigen was 
demasked by incubation for 20 min in vaporized TE buffer followed by staining according to 
Table 18. For development of the antibody labeled sections 100 µl DAB Chromogen and 1 ml 
DAB Substrate buffer were added on the slice for 1 min. The conversion of the substrate leads 
a brown color, which was controlled by microscopy of the slide during staining. When an 
intense brown color was visible the reaction was stopped by covering the slide in tap water. 
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Finally the nuclei were stained by placing the slide in Mayer’s hemalum solution for 2 min 
followed by tap water for 10 min. The sections were dehydrated as described in Table 16 and 
mounted with Roti Histokitt II. After drying slides were ready for microscopy using a Leica DM 
5000B microscope with camera. 
Table 18: Peroxidase staining of CAM tumor sections 
Time Temperature Solution 
15 min rt 1% Hydrogen peroxide in DPBS 
5 min rt Distilled water 
15 s rt DPBS 
30 min rt 2 % Goat serum in DPBS 
15 s rt DPBS 
16 h 4°C CD30 or CD68 in 2 % goat serum in DPBS 
15 s rt DPBS 
1 h rt Goat anti-mouse HRP in 2 % goat serum in DPBS 
15 s rt DPBS 
 
2.3 Protein biochemistry 
2.3.1 Detection of matrix metalloproteinase activity by zymography 
The activity of matrix metalloproteinase (MMP)-9 and MMP-2 was determined in cell culture 
supernatants by gelatin zymography. First, proteins contained in the supernatant were 
separated by molecular weight by SDS-polyacrylamide gel electrophoresis (PAGE). Gel mixes 
listed in  Table 4 were used to prepare 8 % separation gels containing 1 % gelatin and 5 % 
stacking gels. 15 µl cell culture supernatant were mixed with equal amount of loading buffer 
and loaded onto the gel. Electrophoresis was performed at 120 V for 2.5 h with constant 
cooling using freezer packs. Afterwards gels were incubated in wash buffer for 1 h. Gels were 
transferred to renaturation buffer and incubated 1 h. Afterwards gels were covered in 500 ml 
development buffer per gel and incubated over night at 37°C with soft agitation. To visualize 
the gel degradation by MMP activity, the gels were then stained in staining buffer for 1 h, 
followed by destaining in destaining buffer for 1.5 h. Gels were then fixed for 30 min in 
fixation buffer, placed between two cellophane membranes and dried over night. Fixed and 
dried gels were scanned for image processing. 
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2.3.2 Enzyme-linked immunosorbent assay of M-CSF 
M-CSF concentrations in lymphoma CM were measured by enzyme-linked immunosorbent 
assay (ELISA) using Human M-CSF Quantikine ELISA Kit according to the manufacturer’s 
instructions. Optical densities were detected at 450 nm with wavelength correction at 
540 nm using the Tecan Infinite F50 microplate Reader. 
2.4 Molecular biology 
2.4.1 mRNA isolation 
Total RNA from cell pellets was isolated using NucleoSpin RNA kit according to 
manufacturer’s instructions. RNA was eluted using 20 µl RNase free water and concentrations 
were measured with ND-1000. RNA was stored at -80°C. 
2.4.2 Reverse transcription 
SuperScript™ II Reverse Transcriptase was used for cDNA synthesis from total RNA. In brief, 
400 ng – 1 µg RNA was diluted with RNase free water to give a total volume of 10 µl. 
2 µl Random Primer Hexamers were added and samples were denaturated for 10 min at 70°C 
and cooled on ice to allow primer annealing. 8 µl mastermix were added (Table 19) and 
reverse transcription was performed in a Thermocycler T3000 following the program given in      
Table 20. 
Table 19: Reverse transcription mastermix 
Amount Substance 
4 µl 5x First strand 
buffer 
2 µl 0.1M DTT 
1 µl Super Script II RT 
1 µl dNTP mix (each 
10mM) 
 
Table 20: Reverse transcription cycler program 
Temperature Cycle length 
25°C 10 min 
42°C 60 min 
65°C 10 min 
4°C pause 
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2.4.3 Quantitative real-time polymerase chain reaction 
Gene expression was analyzed by SYBR green-based quantitative real-time polymerase chain 
reaction (qRT-PCR) using 7900HT Fast Real-Time PCR System in 384-well plates. Upon 
binding of SYBR green to DNA the resulting complex will absorb blue light (λmax = 488 nm) 
and emit green light (λmax = 522 nm), hence, fluorescence increases in the course of the PCR. 
cDNA samples generated as described in the previous section were diluted to give a solution of 
5 ng/ml. 10 ng cDNA were added to 8 µl qRT-PCR mastermix. The PCR was performed 
following the program given in Table 21. Three qRT-PCRs were analyzed for each sample. 
Table 21: qRT-PCR cycler program 
Temperature Cycle length Number of cycles 
95°C 15 min  
95°C 15 s  
60°C 1 min 40 
95°C 15 s  
60°C 15 s  
95°C 15 s  
 
Gene expression was evaluated using the SDS 2.4 and RQ Manager 1.2.1. Target gene 
transcript abundance was calculated using the ΔΔCT method. CT values of genes of interest 
have been normalized to the CT of a housekeeper. In this study GAPDH was used as a 
housekeeper. 
𝛥𝐶𝑇 = 𝐶𝑇𝑔𝑒𝑛𝑒𝑜𝑓𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 − 𝐶𝑇𝐺𝐴𝑃𝐷𝐻 
Further the changes between treated and untreated control samples were calculated as 
follows: 
𝛥𝛥𝐶𝑇 = 𝛥𝐶𝑇𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 − 𝛥𝐶𝑇𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
The number of cycles exponentially correlates with amount of DNA in the sample, thus, 
relative n-fold changes can be calculated as 
𝑅𝑄 = 2−𝛥𝛥𝐶𝑇 
 
 Material and Methods 
   38 
 
2.4.4 RNA sequencing 
RNA sequencing and normalization 
RNA sequencing (RNA-Seq) was performed by GATC Biotech (Konstanz, Germany). Quality 
assessment, read mapping and normalization was performed by Paula Rubio-Perez. In brief, 
the data from all samples was filtered to generate healthy operational *fastq files. The 
criterions used to filter the data were: to remove RNA impurities a read was removed if it 
matched rRNA_CRUnit.fa exactly, the ends of all reads were inspected and trimmed until the 
base calling quality was above 27, the remaining part was only accepted if it contained less 
than 5 % low quality base callings and obtained the largest N free subsequence of the read 
(accepted if longer than 24 nucleotides). In order to align the data, genome, transcriptome, 
and annotation files were generated as a concatenation of the corresponding Homo sapiens 
(GRCh38, Ensembl release 87) and Drosophila melanogaster reference genomes (BDGP, 
Ensembl release 87). The data was aligned and a count table was created using Kallisto (Bray 
et al. 2016). The data were calibrated using the Drosophila melanogaster Spike-Ins for cell lines 
and GAPDH for macrophage samples where only genes whose count means exceeded 30 reads 
were taken into account. 
Gene set enrichment 
Gene set enrichments were calculated using genes that were differentially expressed in 
L-428 CM derived macrophages and M-CSF derived cells by Log2FC ≥ 1 and Log2FC ≤ -1 in all 
three donors. Annotation of enriched genes to GO terms in biological process, molecular 
function and cellular compartment and InterPro terms and functional annotation clustering 
was performed using online DAVID bioinformatics annotation tool (Huang et al., 2009). EASE 
scores were set to 0.1 and classification stringency to high. Clusters were taken into account if 
at least 5 genes were annotated. 
2.5 Statistical analyses 
Results are shown as mean ± standard deviation (mean ± SD). Statistical analyses have been 
performed using GraphPad Prism 7.03. The statistical significance of the values was 
determined using the Student's t-test. If applicable group results were compared using the 
One-way ANOVA-method with Bonferroni’s post-hoc test to correct for multiple comparisons 
as indicated. Significance levels are indicated as *=p<0.05, **=p<0.01, ***=p<0.001.  
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3 Results 
3.1 Monocytes migrate toward cHL secreted factors 
TAMs are defined as macrophages within or in close proximity to the tumor. Several routes are 
possible for macrophages to occur in the TME: monocytes are recruited by tumor cell secreted 
factors and differentiated into macrophages, macrophages are recruited by tumor cell secreted 
factors, monocytes or macrophages are recruited indirectly by other recruited cell types or by 
cancer associated inflammations. To test for the first option migration of monocytes toward 
different lymphoma conditioned media (CM), five cHL cell lines and two diffuse large B cell 
(DLBCL) cell lines, was investigated in a Boyden chamber assay (Figure 3). Since lymphoma 
cells are cultivated in medium containing 10 % FCS 1 % and 10 % FCS containing medium 
was applied as controls for nutrient dependent migration. Notably, monocytes did not migrate 
in the given time frame of 2 h without any attractant. Offering FCS or lymphoma CM 
monocytes were found to migrate towards any of the given attractants. The migration can be 
enhanced with higher FCS contents, hence, a directed migration toward nutrition is existent. 
Migration is heightened toward L-428, L-1236, L-540, and KM-H2 CM in comparison to 
10 % FCS. Especially L-428 and L-1236 CM are strong chemoattractants for monocytes. 
Migration toward HDLM-2 as well as HBL-1 and OCI-LY3 CM, both DLBCL CMs, are not 
increased compared to 10 % FCS. Thus, cHL CMs with the exception of HDLM-2 CM seem to 
contain factors that are highly attractive for monocytes. The tested DLBCL CMs and 
HDLM-2 CM, however, contain less factors attracting monocytes or in lower concentrations. 
Since the conditioned medium was used pure and lymphoma cells also consume FCS over 
culture time it is not probable that the conditioned medium still contained the originally 
applied 10 % FCS. Thus, it can be suspected that other factors than FCS in the medium of 
HDLM-2, HBL-1 and OCI-LY3 lead to the migration toward these CM which is still significantly 
higher than toward no attractant or 1 % FCS. However, FCS content in the exhausted medium 
was not measured.  
In conclusion, we found that different lymphoma cell lines secret factors to attract monocytes 
to a different extent. All used cHL CMs except HDLM-2 CM were able to attract monocytes, of 
which highest migration was toward L-428 and L-1236 CM. Both tested DLBCL CMs and 
HDLM-2 CM attracted monocytes to a weaker extent comparable to the migration toward 
10 % FCS. 
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Figure 3: Monocytes migrate toward cHL CM. 
A+B: Monocyte migration toward different lymphoma CMs was measured in a Boyden chamber assay with 5 µm 
porous membranes for 2 h (means ± SD, n = 10, one-way ANOVA with Bonferroni’s post-test). 
 
3.2 Monocytes differentiate into macrophages in the presence of 
lymphoma CM 
The previous finding that monocytes migrate toward lymphoma CMs raised the question 
whether after recruitment monocytes are further differentiated by lymphoma secreted factors. 
To investigate if lymphoma cells can secret factors that influence the differentiation of 
monocytes into macrophages CM of the cell lines used in the migration assays were applied on 
freshly isolated primary human monocytes and after 7 d the resulting macrophages were 
counted (Figure 4). As suspected cHL CM does not only attract monocytes but also supports 
the differentiation into macrophages. Namely, differentiation with L-428, L-540, HDML-2 and 
L-1236 CM led to high macrophage numbers whereas KM-H2, HBL-1 and OCI-LY3 CM as well 
as differentiation with recombinant M-CSF led to lower cell numbers. Interestingly, though 
KM-H2 CM was attractive for monocytes in the Boyden chamber assay, differentiation resulted 
in lower macrophage outcome than HDLM-2 CM toward less monocytes migrated. Thus, 
secreted factor that attract or differentiate monocytes might not overlap.  
A B 
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Figure 4: Differentiation of monocytes with various lymphoma CMs leads to differential outcome in cell 
numbers. 
Monocytes were isolated via double gradient centrifugation and each 2 Mio cells were given into a 6-well Teflon 
culture dish either in medium containing 2.5 ng/ml M-CSF or with lymphoma CM mixed in equal parts with fresh 
medium. Cells were incubated for 7 d and afterwards macrophages were counted based on appearance and size 
(mean ± SD, n = 6, paired one-way ANOVA with Bonferroni’s post-test). 
 
We tested the lymphoma cell lines for the expression of growth factors that mediate 
macrophage differentiation. Mainly two endogenous growth factors are described to induce 
the differentiation of monocytes into macrophages, i.e. M-CSF and granulocyte 
macrophage-colony stimulating factor (GM-CSF) (Metcalf 2013). We analyzed the cell lines 
for the gene expression of both growth factors (Figure 5A+C). CSF1 (M-CSF) was found in all 
cell lines except for OCI-LY3 whereas CSF2 (GM-CSF) expression was only found in L-428, 
L-540 and L-1236. We additionally performed an ELISA to determine the concentrations of 
secreted M-CSF in the lymphoma CMs (Figure 5B). In general, the gene expression pattern is 
reflected in the measured M-CSF content of the CMs with highest expression/secretion in 
L-428 and lowest in L-540. An exception are HBL-1 cells which at low level expressed CSF1, 
however, but M-CSF in the CM was not detected, which could be because it was below the 
detection limit of the ELISA (78 pg/ml).  
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Figure 5: Gene expression of CSF1 and CSF2 and M-CSF secretion is most prominent in cHL cell lines. 
(A+C) Gene expression of CSF1 and CSF2 in lymphoma cell lines was measured by qRT-PCR. Expression was 
calculated relative to GAPDH and L-428 cells (mean ± SD, n = 3). (B) M-CSF concentrations in lymphoma CM were 
measured by ELISA (mean ± SD, n = 3). 
 
M-CSF could be one factor to explain the macrophage numbers as the expression patterns is 
loosely reflected in the macrophage count after stimulation. However, it is important to note 
that recombinant M-CSF was used at a final concentration of 2.5 ng/ml which equals the 
amount of M-CSF on monocytes differentiated in the presence of L-428 CM. Yet the 
differentiation with L-428 CM resulted in three times more cells than with M-CSF alone. 
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One factor could be GM-CSF which is on gene expression level only expressed in L-428, L-540 
and L-1236. In this context, the amount of M-CSF in L-540 is relatively low, however it yielded 
similar macrophage numbers like the differentiation with HDLM-2 CM. A reason for this might 
also be the GM-CSF production since the gene is expressed in L-540 cells but not by HDLM-2 
cells. Additionally, there are more macrophages when differentiated with L-540 CM than with 
KM-H2 CM though KM-H2 CM contains twice as much M-CSF. Furthermore, 1.4 ng/ml M-CSF 
and no GM-CSF are applied on monocytes differentiated in the presence of HDLM-2 CM, 
which results in twice as many cells compared to M-CSF alone. In HBL-1 and OCI-LY3 neither 
M-CSF in the CM nor GM-CSF on gene expression level were detected, however, it still 
resulted in notable macrophage amounts. Altogether this shows that the macrophage outcome 
cannot be explained by M-CSF and GM-CSF expression alone. Numerous chemokines and 
cytokines were additionally identified by RNA-Seq to be expressed in L-428 and HBL-1 cells 
(Figure A-19). Among these are factors known to promote macrophage differentiation such as 
VEGFA by both cell lines, IL13 by L-428 cells and IL6 by HBL-1 cells which supports the view 
that several factors in the CMs might contribute to macrophage differentiation. 
In conclusion, monocytes can be differentiated into macrophages in the presence of 
lymphoma CM. Especially differentiation with L-428, L-540, HDLM-2 and L-1236 CM resulted 
in high macrophage numbers. We measured the gene expression of M-CSF and GM-CSF in the 
lymphoma cells as well as the M-CSF content in the CMs. Notable expression was found in the 
cells and CMs that lead to high macrophages numbers. However, the macrophage outcome 
cannot sufficiently be explained by presence of these two growth factors concluding there are 
other factors in the CM also involved in the differentiation process. Accordingly, we found 
multiple factors to be expressed on RNA level in L-428 and HBL-1 cells that could promote the 
macrophage differentiation. 
 
3.3 L-428 CM derived macrophages strongly resemble an M2 phenotype 
3.3.1 Analysis of cell surface markers on M-CSF and L-428 CM differentiated macrophages 
and monocytes 
With the previous experiments we found that cHL cells recruit macrophages to a large extent 
indicating that these cells fulfill functions in the TME. Next we aimed to characterize the cHL 
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differentiated cells in greater detail to identify specific features that account for their functions 
in context of cHL. Monocytes from the same donor were differentiated using M-CSF or 
L-428 CM. Differentiation of monocytes with M-CSF leads to an M2 phenotype in the resulting 
macrophages. TAMs are often referred to expose an M2 phenotype as well (see section 1.1.3). 
First, we determined the morphological properties of the macrophages via flow cytometric 
analysis using the forward scatter (FSC) and sideward scatter (SSC) and microscopy of plated 
cells (Figure 6).  
 
Figure 6: L-428 CM differentiated macrophages are smaller in forward and sideward scatter compared to 
M-CSF cells. 
(A+B) Macrophages were differentiated either with 2.5 ng/ml M-CSF or L-428 CM mixed in equal parts with fresh 
medium for 7 d in Teflon coated cell culture bags and analyzed by flow cytometry concerning appearance in 
forward and sideward scatter (mean ± SD, n = 12, paired t-test, two-tailed). (C) Equal volumes of cell suspensions 
were removed from the cell culture bags and plated on cell culture dishes. Cell were allowed to adhere for 3 h. 
Afterwards cells were washed, fixed and stained with Crystal violet. Representative images are shown. 
 
Macrophages differentiated with L-428 CM appear to be smaller and less granulated by means 
of FSC and SSC than M-CSF derived cells. However, differences in size cannot be seen in 
plated cells. 
Next we analyzed the cells concerning their protein surface expression, intracellular CD68 
expression and gene expression. Figure 7 shows the relative protein expressions of M-CSF and 
L-428 CM derived macrophages as well as of freshly isolated monocytes.  
M-CSF 
L-428 CM 
A B C 
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Figure 7: Surface expression of selected proteins in M-CSF or L-428 CM derived macrophages and freshly 
isolated monocytes. 
Monocytes were isolated by MACS, immediately stained and protein expression was measured by flow cytometry. 
Macrophages were differentiated in Teflon coated cell culture bags with either 2.5 ng/ml M-CSF or L-428 CM 
mixed in equal parts with fresh medium. Macrophages were extracted from the cell culture bags after 7 d and 
immediately stained for flow cytometric analysis (mean ± SD, n = 12, paired t-test, two-tailed). 
 
Expression of maturation markers 
CD14, CD11b, CD11c and CD68 were markers selected to monitor the differentiation state of 
the two macrophages types and monocytes. Naturally, the CD14 expression in monocytes is 
notably higher than in the macrophages as this marker decreases during the differentiation 
process. The resulting macrophages, however, show no differential expression. Additionally, 
CD11b is known to behave conversely and is upregulated during the differentiation process in 
macrophages which we also observed. CD11c another maturation marker shows no major 
changes after differentiation but a small significant increase in L-428 CM derived macrophages 
compared to M-CSF derived cells. CD68, a pan macrophage marker, is at low level also 
expressed in monocytes and as anticipated upregulated in mature macrophage. Also here a 
higher expression in L-428 CM derived compared to M-CSF derived can be detected. 
M2 marker expression 
Two commonly used surface markers to detect the M2 activation state of macrophages are 
CD163 and CD206. Both markers are strongly upregulated upon differentiation from 
monocytes to macrophages. Of note, CD163 is the highest expressed marker in this panel. 
Importantly, CD206 is about three fold higher expressed on L-428 CM macrophages than on 
M-CSF derived macrophages and shows the strongest differential expression in this panel. It is 
not detected on monocytes. 
Expression of antigen presenting and co-stimulatory/-inhibitory molecules 
The markers human leukocyte antigen (HLA)-DR, CD1a, CD40, CD80, CD86 and PD-L1 are 
involved in communication of macrophages with T cells by antigen presentation or as 
co-stimulatory/-inhibitory molecules. Interestingly, we see an increased expression in CD1a, 
CD80, PD-L1 and CD40 in L-428 CM differentiated cells compared to M-CSF derived cell and 
monocytes suggesting enhanced interactions with T cell which are a dominant factor in the 
cHL microenvironment. Notably, CD40 a co-stimulatory molecule is also upregulated which is 
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a marker for M1 activation of macrophages. Furthermore, CD1a commonly used as a DC 
marker is not expressed on monocytes and M-CSF derived macrophages but was detectable on 
L-428 CM derived cells. 
Expression of adhesion markers 
In order to further evaluate functional properties, especially those connected to cell adhesion, 
four adhesion markers were tested in this experiment namely CD31, CD33, CD44 and CD54. 
Strikingly all these markers are increased in L-428 CM macrophages compared to M-CSF 
macrophages. However, all markers except CD54 are decreased compared to monocytes which 
means a downregulation overall in the differentiation process. Still the consequent 
upregulation comparing the two macrophages types suggests a functional distinction of these 
cell types and a special requirement of L-428 cells to educate macrophage with advanced 
properties in cell-cell or cell-matrix interactions. 
In summary, application of L-428 CM or M-CSF on monocytes led to the expected changes in 
the expression of surface markers commonly used to monitor macrophages differentiation. 
This shows that after 7 d mature macrophages are derived. These cells are M2 activated as 
seen by high expression of CD163 and CD206. Comparing M-CSF and L-428 CM differentiated 
macrophages a number of proteins are upregulated in L-428 CM derived cells. The higher 
expression of CD1a, CD80, CD40 and PD-L1 hints toward functions of the macrophages in 
T cell interaction, the expression of CD11c, CD206, CD33, CD44 and CD54 toward functions 
that require improved cell-matrix or cell-cell interactions. The other markers analyzed were 
not differentially expressed, notably, there was no lower expression in any protein on 
L-428 CM derived cells compared to M-CSF cells. 
 
3.3.2 Gene expression of M1 and M2 markers in M-CSF and L-428 CM derived 
macrophages  
To further estimate the activation state of M-CSF and L-428 CM macrophages gene expression 
analysis of markers, which could not be detected by flow cytometry, was performed. TNF-α, 
IL1-β, IL-8 (gene name CXCL8) and CCR7 characterize the M1 activation status. No differential 
expression was found in the respective genes, only CCR7 seems to be lower expressed in 
L-428 CM macrophages compared to M-CSF cells. IL10 and VEGFA further define the M2 state 
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of macrophages. No differences in the expression of VEGFA were found. IL10 is highly 
expressed in M2 activated macrophages, here, was lower expressed in L-428 CM than in 
M-CSF cells. Overall, the gene expression analysis of the selected markers confirms the M2 
activational state of L-428 CM derived macrophages. 
 
Figure 8: Gene expression of selected markers shows no differences between M-CSF and L-428 CM derived 
macrophages. 
Macrophages were differentiated in Teflon coated cell culture bags with either 2.5 ng/ml M-CSF or L-428 CM. 
Macrophages were extracted from the cell culture bags after 7 d and plated on cell culture dishes. After 3 h 
non-adherent cells were washed off the dish and adherent were immediately lysed for RNA extraction and gene 
expression analysis by qRT-PCR. Expression is relative to GAPDH and M-CSF macrophages (mean ± SD, n = 12). 
 
TNF IL1B CXCL8 CCR7 
IL10 VEGFA 
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3.3.3 Transcriptional changes in L-428 CM derived macrophages compared to M-CSF and 
HBL-1 CM derived cells 
We used a second approach to characterize differentiated macrophages in detail by detecting 
genome wide gene expression changes. Monocytes from three different donors were 
differentiated with L-428 CM, M-CSF and HBL-1 CM and gene expression was measured by 
RNA-Seq. In order to define which genes are altered in their expression the top differentially 
expressed genes were extracted based on their Log2FC being ≥ 1 and ≤ -1 in all three donors. 
In total we found 276 genes to be differentially expressed in L-428 CM compared to M-CSF 
derived macrophages in the three donors of which the majority, 249 genes, were upregulated 
and 27 genes were downregulated (Figure 9A). 
To gain more insight into the functions of the altered transcripts we performed a gene 
enrichment analysis and functional annotation clustering using DAVID to identify enriched 
gene ontology terms and InterPro domains (Figure 9B). We found that the top enriched GO 
terms and InterPro domains are mainly concerned with leukocyte interactions, antigen 
processing and presentation, peptidase activity and enrichment in MHC, C-type lectin and 
peptidase domains. This supports the hypothesis based on the protein expression analysis that 
L-428 CM derived cells are primed to mediate leukocyte interaction, specifically T cell 
interactions, indicated by GO terms assigned to biological processes (see full cluster in Figure 
A-21). Furthermore, several terms are connected to MHC complex and antigen presentation. 
Among the top terms we also find enrichment in genes whose products are connected to 
intracellular membranes and enriched domains belong aside from the MHC complex, to C-type 
lectins and peptidase. This hints toward endocytic processes, that could either serve antigen 
presentation or matrix degradation.  
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Figure 9: Global gene expression analysis reveals upregulation of genes in L-428 CM derived macrophages 
involved in leukocyte activation, antigen presentation and endocytosis. 
(A) Venn diagrams of upregulated and downregulated genes in L-428 CM derived macrophages compared to M-CSF 
derived cells from three donors. (B) GO term and InterPro enrichment analysis calculated by DAVID online 
annotation tool for the overlap in (A) is shown. The top five clusters by enrichment score and their three top terms 
by P-value are depicted. Complete clusters are shown in the appendix Figure A-21 and Figure A-22. (C) Heatmap of 
differentially expressed genes in L-428 CM derived macrophages compared to M-CSF and HBL-1 CM derived cells 
from three donors (#1, #2, #3) assigned to the first GO term biological process cluster (D) Heatmap of 
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Figure 9C shows the heatmap of genes annotated to the leukocyte activation cluster. Among 
them we find a striking number of HLA genes and additionally a number of co-stimulatory 
and -inhibitory molecules such as CD80, CD86 and CD274 (PD-L1). It has to be argued though 
that some of these were analyzed for their surface expression such as HLA-DR, CD80, CD86 
and PD-L1 and we found only CD80 and PD-L1 to be increased on L-428 CM derived 
macrophages compared to M-CSF derived cells. This means the identification of upregulated 
genes by RNA-Seq does not per se correlate with enhanced protein expression. However, the 
number of upregulated genes that have been identified to be involved in leukocyte interaction 
and antigen presentation strongly indicates the functional relevance of L-428 CM derived 
macrophages in leukocyte and T cell communication.  
Figure 9D depicts the genes annotated to the C-type lectin cluster. Here we find as the top 
upregulated gene MRC1 which is in accordance with the strong induction of CD206 on the 
surface of L-428 CM educated macrophages compared to M-CSF cells. Additionally, several 
C-type lectin-like domain-containing proteins (CLEC) are upregulated in L-428 CM derived 
macrophages. This suggests enhanced carbohydrate binding and uptake of the cells. 
Interestingly, we find most genes differentially expressed in L-428 CM differentiated 
macrophages compared to M-CSF derived cells are up- and downregulated the same way 
compared to HBL-1 CM derived cells. Thus, the proposed functions might be a specific feature 
of cHL educated macrophages. 
Overall, the global analysis of transcriptional changes supports the view that L-428 CM derived 
macrophages have been primed to fulfill function in leukocytes, especially T cell interactions, 
and have altered endocytic behavior accounting for antigen uptake or matrix degradation. 
 
3.4 Functional properties of L-428 CM and M-CSF derived macrophages 
3.4.1 L-428 CM and M-CSF differentiated macrophages can be repolarized toward the 
M1 type 
Macrophages are known to expose a high plasticity reacting to various stimuli leading to 
changes in their phenotype and behavior. However, there is still some controversy about 
whether switching from any phenotype to another is possible under any given circumstance or 
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if fully activated cells rather undergo apoptosis. In order to test whether L-428 CM derived 
macrophages can still react toward danger signals and switch to an M1 phenotype LPS and 
interferon-γ (IFN-γ) were applied on L-428 CM and M-CSF differentiated cells. Stimulation led 
to the upregulation of all classical M1 markers in both macrophage types and almost to the 
same extent (Figure 10). This indicates that the cells possess the plasticity to switch into other 
phenotypes here namely toward M1 activation. 
 
Figure 10: M-CSF and L-428 CM differentiated macrophages can be activated toward the M1 type. 
Macrophages were differentiated in Teflon coated cell culture bags with either 2.5 ng/ml M-CSF or L-428 CM 
mixed with equal volumes of fresh medium. Macrophages were extracted from the cell culture bag after 7 d and 
plated on cell culture dishes. After 3 h non-adherent cells were washed off the dish and adherent cells were 
stimulated with 100 ng/ml LPS and 10 ng/ml IFN-γ for 24 h. Gene expression analysis was measured by qRT-PCR. 
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3.4.2 Endocytosis of specific targets is enhanced in L-428 CM macrophages 
Several markers were shown to be upregulated in L-428 CM derived macrophages compared 
to M-CSF derived cells (section 3.3.1). This includes CD11c, that belongs to the integrin family 
regulating matrix cell interactions, and the tested adhesion markers, CD33, CD44 and CD54. 
The highest differential expression was observed for the mannose receptor CD206 which is 
binds to various substrates leading to their ingestion. Analysis of global gene expression 
changes between L-428 CM derived macrophages and M-CSF cells, additionally showed an 
enrichment of genes that are involved in antigen processing, localized in the endocytic 
compartment and an enrichment of C-type lectin domains. Taken together this hints toward an 
altered endocytic capacity of L-428 CM derived macrophages. 
 
Figure 11: No differences in the uptake of polar beads between M-CSF and L-428 CM derived macrophages. 
Macrophages were differentiated in Teflon coated cell culture bags with either 2.5 ng/ml M-CSF or L-428 CM 
mixed with equal volumes of fresh medium. Macrophages were extracted from the cell culture bag after 7 d and 
plated on cell culture dishes. After 3 h non-adherent cells were washed off the dish and adherent cells were 
incubated with 5 Latex beads per cell for 2 h at 37°C or on ice. Fluorescence was measured by flow cytometry. 
Amounts of phagocyting cells and distribution of ingested beads were calculated by subtracting percentages of cells 
kept on ice from cells incubated at 37°C (mean ± SD, n = 12). 
 
To test whether L-428 CM educated macrophages are characterized by different endocytic 
capacities compared to M-CSF differentiated cells different endocytosis assays were applied. 
First carboxylate modified fluorescently labeled latex beads were used to monitor the 
phagocytic activity. The weak negative charge on the surface of the beads leads to binding of 
A B 
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positively charged proteins of the surrounding medium and the accumulation of water 
molecules. Therefore several pathways for detection and ingestion can be triggered by these 
beads. Figure 11 shows the uptake of beads by L-428 CM and M-CSF derived macrophages. 
There are no differences in the percentage of cells taking up latex beads. The distinct size of 
the beads furthermore allows the discrimination of how many beads have been taken up as the 
increasing fluorescence intensity with each bead is resolved in distinct peaks. However, also 
the numbers of beads ingested does not differ between L-428 CM and M-CSF derived 
macrophages suggesting that overall the ability for the uptake of particles is not altered. 
 
Figure 12: Uptake of FITC-dextran is enhanced in L-428 CM derived macrophages compared to M-CSF cells. 
Macrophages were differentiated in Teflon coated cell culture bags with either 2.5 ng/ml M-CSF or L-428 CM 
mixed with equal volumes of fresh medium. Macrophages were extracted from the cell culture bag after 7 d and 
plated on cell culture dishes. After 3 h non-adherent cells were washed off the dish and adherent cells were 
incubated with 1 mg/ml 10 kDa or 70 kDa FITC-dextran for 2 h at 37°C or on ice. For blocking mannose was given 
10 min prior to dextran. Fluorescence was measured by flow cytometry. Mean fluorescence intensity ratios (MFIR) 
were calculated dividing the MFI of a 37°C sample by the MFI of the corresponding sample kept on ice (mean ± SD, 
n = 12, paired one-way ANOVA with Bonferroni’s post-test). 
 
Since L-428 CM cells showed a strong induction in CD206 we hypothesized that the uptake of 
sugars could be increased in these cells because of enhanced target binding. CD206 is a 
mannose receptor but has been described to bind other sugars as well. In DCs an increased 
uptake of dextran was connected to CD206 expression on these cells (Kato et al. 2000). 
Therefore, we applied labeled 10 and 70 kDa size dextran on macrophages and measured the 
10 kDa FITC-dextran 70 kDa FITC-dextran 
A B 
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uptake by flow cytometry. As mannose still has a higher binding affinity to CD206 in parallel 
unlabeled mannose was added prior to dextran to test whether it blocks the dextran uptake. 
Macrophages differentiated with L-428 CM ingested significantly more dextran than M-CSF 
derived cells (Figure 12). Additionally, the uptake could be partially blocked in the presence of 
mannose indicating that indeed the higher dextran ingestion is mediated by CD206. Different 
dextran weights were used for this assay suggesting that several endogenous molecules can be 
affected as tested here within a range of 10 kDa to 70 kDa. 
In conclusion, M-CSF and L-428 CM derived cells possess similar properties concerning the 
uptake of particles as seen by the ingestion of beads with non-specific surface labeling. The 
uptake of CD206 specific targets, however, is enhanced in L-428 CM derived cells, which is in 
accordance with their high surface expression. 
 
3.4.3 Collagen uptake is enhanced in L-428 CM derived macrophages and macrophages 
secret high amounts of MMP-9 
Beside the uptake of sugars CD206 was described to contribute to the collagen uptake in 
murine bone marrow derived macrophages (section 1.2.2). Thus, we used labeled gelatin to 
investigate if the uptake of collagen differs between M-CSF and L-428 CM differentiated 
macrophages. As expected the collagen uptake was significantly higher in L-428 CM derived 
cells than in M-CSF cells (Figure 13A). The enhanced uptake of collagen suggests that the 
upregulation of CD206 in macrophages by L-428 CM could be an important aspect of matrix 
remodeling in cHL. Hence, we analyzed the secretion of matrix metalloproteinase (MMP)-9 
and MMP-2 by zymography using gelatin containing gels. MMP-2 was not detected. MMP-9 
was detected and is secreted by macrophages, but there was no differential expression 
between M-CSF and L-428 CM educated cells (Figure 13B). However noteworthy is that in 
comparison to L-428 cells itself macrophages secret very high amounts of MMP-9. Both 
findings indicate that L-428 CM associated macrophages could play a role in tissue 
reorganization. 
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Figure 13: Collagen uptake is enhanced in L-428 CM derived macrophages and macrophages secret high 
amounts of MMP-9. 
(A) Macrophages were differentiated in Teflon coated cell culture bags with either 2.5 ng/ml M-CSF or L-428 CM 
mixed with equal volumes of fresh medium. Macrophages were extracted from the cell culture bag after 7 d and 
plated on cell culture dishes. After 3 h non-adherent cells were washed off the dish and adherent cells were 
incubated with 5 µg/ml gelatin OG-488 conjugate for 30 min at 37°C or on ice. Fluorescence was measured by flow 
cytometry. Mean fluorescence intensity ratios (MFIR) were calculated dividing the MFI of a 37°C sample by the MFI 
of the corresponding sample kept on ice (mean ± SD, n = 5, paired t-test, two-tailed) (B) MMP-9 levels in 
macrophage and lymphoma CM were analyzed by zymography. 
 
3.4.4 Co-culture of L-428 cells and macrophages in an in vivo chorion allantois membrane 
assay leads to altered tumor formation 
A direct co-culture of cHL cells and macrophages was applied to investigate the tumor 
formation in a CAM assay. L-428 cells alone or with macrophages were suspended in a 
collagen gel and applied on the CAM of chicken eggs. After four days by macroscopic 
examination tumor size and vascularization can be determined. Histological processing and 
immunohistochemical staining of tumors show the intratumoral structure and organization of 
cells. Figure 14A shows representative images of tumors formed on the CAM and trichrome 
stained tumor sections. By visual inspection the co-culture tumors appear to be smaller with 
less hemorrhages. In the stained tumor sections we found that the co-culture tumors are 
furthermore less densely packed with cells than the L-428 tumors. We measured the tumor 
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Peroxidase staining of CD30 and CD68 on tumor sections show a compartmentalization of the 
tumor (Figure 14D). CD30 positive L-428 cells are located in the upper and lower parts of the 
tumor but are almost absent in the central area. CD68 positive macrophages dominate the 
upper and central part and are mainly present in the remaining collagen gel and in close 
proximity to it. In the L-428 tumor the cells are evenly distributed throughout the tumor.  
 
Figure 14: Addition of macrophages alters tumor formation of L-428 cells in an in vivo CAM assay. 
(A) Representative stereomicroscopic (7.8x magnification) and trichrome stained pictures of L-428 and L-428 CM 
derived macrophages (Mφ). Rectangles indicate the magnified area of the image. (B+C) Tumor area and 
hemorrhage score were quantified from stereomicroscopic images (mean ± SD, L-428: n = 19, L-428 + Mφ: 
n = 31, B: two-tailed t-test with Welsh’s correction, C: Mann-Whitney test). (D) Representative CD30 and CD68 
peroxidase stained images of L-428 tumor with and without macrophages (12.5x magnification). 
 
In conclusion, we found an altered tumor formation when adding macrophages to L-428 cells 
in a CAM assay but contrary to the expectation we found the co-culture tumors to be smaller 
with less bleedings and less cells in the tumor mass. The structural differences in the tumors 
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indicate a mutual interaction of L-428 cells with macrophages and support the proposed 
function of macrophages in tissue remodeling processes. However, the significance is unclear, 
since macrophages are not beneficial for the tumor growth in this CAM assay by means of the 
tumor size. 
 
3.5 CD206 expression on L-428 CM derived macrophages 
In the previous section we described a high expression of CD206 on L-428 CM derived 
macrophages compared to M-CSF derived cells. Additionally, we observed enhanced endocytic 
activity connected to this increased expression. Therefore we aimed to identify potential 
factors in cHL CM that can induce CD206 expression on macrophages. 
3.5.1 IL-13 induces gene and cell surface expression of CD206 
A characteristic and distinguished feature of cHL is the secretion IL-13 (Skinnider et al. 2002). 
Additionally, macrophages are known to be polarized toward an M2 phenotype by IL-13 which 
includes an upregulation of CD206. Hence, we questioned if high CD206 expression is a direct 
result of IL-13 stimulation which is produced by cHL cells. We isolated and stimulated 
monocytes with M-CSF and IL-13 or a combination in direct comparison to L-428 CM 
stimulated cells. Figure 15A shows the result for MRC1 (CD206) gene expression after 6 h, 
24 h and 7 d of stimulation. As already seen in section 3.3.1 CD206 is not expressed on the 
cell surface of monocytes. There is also no detectable gene expression in unstimulated and 
M-CSF stimulated monocytes after 6 h. Interestingly, gene expression of CD206 can be found 
after 24 h in these cells suggesting there is an endogenous factor that can trigger the 
expression. IL-13 stimulation results in an induction of MRC1 expression leading to its 
detection after 6 h, expression is further enhanced after 24 h and downregulated after 7 d. 
Notably, addition of M-CSF does affect CD206 expression neither alone nor in combination 
with IL-13. L-428 CM shows the same pattern like IL-13 stimulation, however, CD206 
expression is about ten times higher after 6 h and two times higher after 24 h. Since the used 
concentrations of IL-13 is with 10 ng/ml higher than published concentrations measured in 
L-428 CM it is most likely that the induction in CD206 gene expression is not solely due to 
secreted IL-13 but other factors in the CM also activate CD206 gene expression (Kapp et al. 
1999). 
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Figure 15: CD206 gene and surface expression is induced by IL-13 and L-428 CM.  
(A) Monocytes were stimulated with 2.5 ng/ml M-CSF, 10 ng/ml IL-13 or both or L-428 CM for the indicated time. 
Gene expression of MRC1 was analyzed by qRT-PCR. Expression is relative to GAPDH and L-428 CM treated cells 
(mean ± SD, n = 5). (B) Monocytes were seeded in Teflon coated cell culture bags with 2.5 ng/ml M-CSF, 
10 ng/ml IL-13 or both or L-428 CM mixed with equal volumes of fresh medium. Aliquots were taken at the 
indicated time points and stained for CD206 expression. MFIRs were calculated by dividing the MFI of CD206 by 
the MFI of the isotype control (mean ± SD, n = 6, paired one-way ANOVA with Bonferroni’s post-test). 
 
CD206 surface expression was also measured after 24 h and 7 d (Figure 15B). In concordance 
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L-428 CM treated cells after 24 h but not in untreated controls or M-CSF stimulated cells. 
Again in L-428 CM treated cells the CD206 expression is higher than in IL-13 treated cells by 
about four times. The expression is further increased after 7 d and at that time point also 
measurable in unstimulated and M-CSF treated cells. In general the expression pattern seen 
after 24 h is repeated with low expression on untreated and M-CSF treated monocytes, higher 
expression on IL-13 treated cells and highest expression on L-428 CM treated cells. In 
combination with the measured gene expression this suggests that CD206 accumulates on the 
cells surface while the transcription is down regulated. 
To conclude, IL-13 but nor M-CSF activates CD206 gene expression in monocytes within 6 h 
which is otherwise absent in these cells. L-428 CM does the same, however, to a much greater 
extent. The expression increases further within 24 h and is at that time point also measurable 
in unstimulated and M-CSF treated cells. The CD206 surface expression largely resembles this 
gene expression pattern at 24h with increasing expression from day 1 to day 7. These findings 
indicate that IL-13 indeed might be a factor in L-428 CM that up-regulates CD206 expression, 
however, other factor must be involved in this process leading to a higher expression of CD206 
in L-428 CM treated compared to IL-13 treated monocytes. 
 
3.5.2 MRC1 expression is abolished in monocytes treated with JAK inhibitors 
IL-13 is known to bind to a heterodimer of IL-4 receptor α (IL4Rα) and IL-13 receptor α 
(IL13Rα) which is associated intracellularly with Janus kinase (JAK)1, JAK2 and tyrosine 
kinase 2 (TYK2) (Bhattacharjee et al. 2013). Therefore we used two JAK inhibitors namely 
Pyridone-6 which inhibits JAK1, JAK2, JAK3 and TYK2 and Ruxolitinib which inhibits JAK1 
and JAK2 to test whether MRC1 expression can be blocked in IL-13 and L-428 CM treated 
cells. Clearly, MRC1 expression is present after 6 h only in IL-13 and L-428 CM treated cells 
and remains absent in cells treated with a JAK inhibitor (Figure 16). As mentioned in the 
previous section other factors than IL-13 in L-428 CM are likely to be involved in CD206 
induction. However, also in L-428 CM treated cells MRC1 expression is blocked after JAK 
inhibition. Hence, JAK1 and JAK2 activity is essential for induction of MRC1 gene expression 
and additional factors in L-428 CM induce the expression in an JAK1 or JAK2 dependent 
manner. 
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Figure 16: Inhibition of JAKs prohibits MRC1 expression in monocytes. 
Monocytes were preincubated with DMSO or inhibitors for 1 h before 10 ng/ml IL-13 or L-428 CM was added for 
6 h. Gene expression of MRC1 was analyzed by qRT-PCR. Expression is relative to GAPDH and L-428 CM treated 
cells (mean ± SD, n = 6). 
 
3.5.3 CD206 expression after stimulation with cHL and DLBCL CMs 
We further tested the five cHL and two DLBCL cell lines used in section 3.1 and 3.2 if an 
induction of CD206 expression can be observed (Figure 17A). The CMs derived from L-428, 
L-540, HDLM-2 and L-1236 could all induce MRC1 expression in monocytes after 6 h. 
Strongest effects on MRC1 expression occurred after L-428 and L-1236 CM stimulation 
whereas cells stimulated with L-540 and HDLM-2 CM expressed about one fifth to one tenth 
less MRC1. However, also in these cells the MRC1 expression is detectable while it is absent in 
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Figure 17: Monocytes increase CD206 gene and surface expression after stimulation with cHL CM. 
(A) Monocytes were stimulated with cHL CM for 6 h. Gene expression of MRC1 was analyzed by qRT-PCR. 
Expression is relative to GAPDH and L-428 CM treated cells (mean ± SD, n = 6). (B) Gene expression of IL13 was 
analyzed in lymphoma cell lines by qRT-PCR. Expression is relative to GAPDH and L-428 cells (mean ± SD, n = 3). 
(C) Monocytes were stimulated with cHL CM for 7 d. CD206 surface expression was analyzed by flow cytometry. 
MFIRs were calculated dividing the MFI of CD206 by the MFI of the isotype control (mean ± SD, n = 6, paired one-
way ANOVA with Bonferroni’s post-test). 
 
We next analyzed the gene expression of IL-13 in the cell lines (Figure 17B). Interestingly, in 
accordance with the induction of MRC1 expression in monocytes IL-13 expression was only 
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and OCI-LY3 cells. Notably, IL-13 gene expression is highest in HDML-2 while in L-1236 the 
expression is about 80 % lower though they have opposite effects on the MRC1 expression in 
monocytes. The amount of secreted protein does not necessarily reflect the gene expression 
that means concentrations might still be lower in the HDLM-2 CM than in L-1236 or 
L-428 CM. However, as stated in the previous section other factors might be involved in the 
induction of MRC1 expression. One factor in this context might be GM-CSF which was 
reported to increase CD206 expression on human monocytes (Däbritz et al. 2015). 
Interestingly, gene expression of CSF2 (GM-CSF) was only found in L-428, L-540 and L-1236 
but none of the other cell lines and was highest in L-1236 which also showed the strongest 
induction of MRC1 expression in monocytes (Figure 5). 
Finally, we screened the CM treated monocytes for CD206 expression on the cell surface after 
7 d. Figure 17C shows the results of the flow cytometric analysis. As already observed after 7 d 
all differentiated macrophages express CD206 on the cell surface. A higher expression of 
CD206 is seen on cell treated with the four cHL CMs that also induced the gene expression 
after 6 h compared to M-CSF treated cells and the remaining three CM that induced no CD206 
expression initially. However the differences in the CD206 gene expression after 6 h, namely 
high induction in L-428 and L-1236 CM stimulated cells compared to lower induction L-540 
and HDLM-2 CM stimulated cells, is not further reflected. There is only a tendency for 
HDLM-2 and L-540 treated cells to express less CD206. 
In conclusion, we showed that four out of five cHL CMs can induce CD206 gene expression in 
monocytes. Notably, these four cell lines were expressing IL13. Additionally, three of these cell 
lines also express CSF2 which has been described to induce CD206 gene expression. Finally, 
macrophages that were derived from CM of these four cHL cell lines express more CD206 on 
their cell surface. 
 
3.6 Recruitment of macrophages and repolarization by lymphoma 
secreted factors 
As mentioned in section 3.1 several mechanisms of how macrophages reach the TME are 
proposed and we showed that monocyte recruitment might be one possible way. We also 
tested whether macrophages could be attracted by lymphoma secreted factors as well. 
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Therefore we differentiated macrophages using M-CSF and assessed the migration toward 
lymphoma CM in Boyden chamber assays (Figure 18A). First, there is a measurable migration 
of cells without addition of chemoattractants which was absent in monocytes. Additionally, the 
migration toward 10 % FCS is relatively low, hence, FCS is not as attractive for macrophages 
as for monocytes and directed movement rather requires specific chemoattractants. Movement 
toward L-428 and L-1236 CM was again highest as it was seen for monocyte whereas 
movement toward HBL-1 and OCI-LY3 CM is lower, however, it is still higher than toward FCS 
indicating that DLBCL cells secret chemoattractants as well. 
 
Figure 18: Macrophages migrate toward lymphoma CM and increase CD206 gene expression after 
stimulation with cHL CM. 
(A) Macrophage migration toward different lymphoma CMs was measured in a Boyden chamber assay with 
collagen coated 5 µm porous membranes for 2 h (means ± SD, n = 6, one-way ANOVA with Bonferroni’s post-test). 
(B) Macrophages were stimulated with lymphoma CM for 24 h. Gene expression of MRC1 was analyzed by 
qRT-PCR. Expression is relative to GAPDH and L-428 CM treated cells (mean ± SD, n = 4). 
 
Since we saw a strong induction of CD206 with cHL CM we tested if macrophages also 
increase the MRC1 expression in the presence of cHL CM meaning if they can be repolarized 
after recruitment by HL cells (Figure 18B). We observed an increased expression of MRC1 in 
A B 
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macrophages after stimulation with cHL CM and an unaltered gene expression with 
DLBCL CM. 
Taken together, both findings hint toward an attraction and repolarization of fully 
differentiated macrophages by cHL cells resulting in an increased CD206 expression in these 
cells. Besides also DLBCL cells secret factors that attract macrophages. 
 
4 Discussion 
The aim of this study was to investigate the recruitment and activation of macrophages by 
lymphoma derived factors. We found that cHL cells attract and differentiate monocytes in high 
numbers. Additionally, macrophages were attracted and repolarized by cHL CM. 
A distinguished feature of cHL derived macrophages was a high CD206 expression 
accompanied by high endocytic uptake of CD206 substrates. Furthermore, we found that IL-13 
contained in cHL CM could be one factor that leads to high CD206 expression. The impact of 
these findings for cHL development and progression will be discussed below. 
4.1 Recruitment and differentiation of macrophages by lymphoma 
secreted factors 
4.1.1 Recruitment of monocytes and macrophages by chemoattractants in lymphoma CM 
In this study we found that monocytes as well as macrophages actively move toward 
lymphoma CM in Boyden chamber assays. This is in concordance with previous findings 
indicating active recruitment of monocytes or macrophages into the tumor by tumor cell 
secreted factors (Estko et al. 2015; Gazzaniga et al. 2007; Wang et al. 2014; Tripathi et al. 
2014). Whether the main source for TAMs in vivo is recruitment of circulating monocyte or 
tissue resident macrophages is still discussed. Several studies carried out in mice proposed that 
mainly monocytes are recruited by tumor cell derived CCL2 (Tymoszuk et al. 2014; Alonso-
Nocelo et al. 2018; Franklin et al. 2014). Interestingly, L-428 and HBL-1 cells analyzed by 
RNA-Seq showed no expression of CCL2 and no CCR2 expression was detectable in CM or 
M-CSF derived macrophages. Loss of CCR2 on in vitro M-CSF differentiated human 
macrophages was reported before and here also occurred after CM treatment though HBL-1 
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cells had no detectable M-CSF (Sierra-Filardi et al. 2014). There is currently no evidence for 
the presence of CCR2+ tissue resident macrophages in humans but their occurrence was 
demonstrated in mice (Li et al. 2016; Conrad et al. 2007; Wei et al. 2016). In tumor sections 
of cHL CCL2 mRNA was detected and human primary monocytes express CCR2 on their 
surface (Luciani et al. 1998; Appleby et al. 2013). Thus, recruitment of monocytes via 
CCL2-CCR2 interactions might still play a role in vivo, but in these experiments cannot explain 
their attraction by L-428 and HBL-1 CM and in general the attraction of macrophages. Other 
chemokines that are expressed by these cell lines and could attract monocytes or macrophages 
include chemokine (C-X3-C motif) ligand 1 (CX3CL1) by both cell lines and CCL5 by L-428 
cells. CX3CL1 has been found to be expressed in several cancers such as neuroblastoma, 
colorectal cancer and chronic lymphocytic leukemia (Ferretti et al. 2014). Its receptor 
chemokine (C-X3-C motif) receptor 1 (CX3CR1) is expressed on CD14+ monocytes and 
CX3CL1 has been shown to attract monocytes to inflammatory sites (D’Haese et al. 2010). Its 
role in the recruitment of monocytes to the tumor site, however, remains unclear. Importantly, 
CX3CL1 can exist in a membrane-bound and a soluble form. Expression of the 
membrane-bound form on tumor cells mediates direct cell-cell interactions with the 
microenvironment (Ferretti et al. 2011). In order to be chemotactic the ligand must be 
released from the cell surface. Shedding of CX3CL1 from the membrane is mediated by 
ADAM10 and ADAM17, both genes are also expressed by L-428 and HBL-1 cells (data not 
shown). Therefore the occurrence of the soluble form in lymphoma CM can be assumed which 
would lead to an attraction of monocytes. CCL5 has been previously found to be expressed in 
cHL cell lines as well as in tumor sections of cHL and was proposed to attract mast cells to the 
tumor (Maggio et al. 2002; Fischer et al. 2003). It is also known to attract monocytes, notably, 
Met-RANTES, a chemokine receptor antagonist, was found to suppress the CCL5 dependent 
recruitment of monocytes in transplant mice models (Gröne et al. 1999; Stojanovic et al. 
2002). As CCL5 secretion was already shown in several Hodgkin cell lines it can be proposed 
that it led to the attraction of monocytes in our experiment which could be further tested by 
the introduction of Met-RANTES into the experimental setup. It could also play a role in in 
vivo recruitment of monocytes in cHL as it was detected in patient samples. Beside chemokines 
other factors have been shown to be chemoattractants for monocytes or macrophages. 
Notably, M-CSF which is expressed by all cHL cell lines were shown to be chemotactic for 
monocytes and macrophages (Pixley 2012). Additionally, TNF-α and VEGF-A were found to 
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attract monocytes or macrophages and are also expressed by L-428 and HBL-1 cells (Ming et 
al. 1987; Barleon et al. 1996; Yang et al. 2004). 
Taken together, our results show that cHL cells and also DLBCL cells produce factors to attract 
monocytes and macrophages into their environment. Potentially a mixture of various factors 
account for the attraction of monocytes and macrophages in these experiments. The widely 
proposed CCL2-CCR2 axis does not play a role in this context for the attraction of 
macrophages or attraction of monocytes by L-428 CM. Since we observed migration of both 
cell types toward lymphoma secreted factors, whether the occurrence of TAMs in vivo results 
from attraction of circulating monocytes or tissue macrophages cannot be concluded, both 
mechanisms are possible. 
4.1.2 Differentiation of monocytes into macrophages by lymphoma derived factors 
A key finding of this study is that differentiation of monocytes into macrophages can occur in 
the presence of lymphoma CM and is especially promoted by cHL CM. The differentiation of 
macrophages by lymphoma secreted factors is in concordance with in vitro studies of other 
entities such as small cell lung cancer and pancreatic cancer where the malignant cells likewise 
secret factors that promote differentiation (Kuen et al. 2017; Hamilton et al. 2016). 
Additionally, a number of mouse studies found circulating monocytes to infiltrate the tumor 
thereby differentiating into macrophages (Afik et al. 2016; Madsen et al. 2017; Franklin et al. 
2014). In our experiments strikingly high macrophage amounts were found after 
differentiation with cHL CMs. We showed that M-CSF a growth factor known to promote 
macrophage differentiation is highly expressed by cHL cells. Increased M-CSF expression is a 
feature in several cancers (El-Gamal et al. 2018). Likewise elevated M-CSF serum levels in cHL 
patients have been reported and HRS cells were found to be M-CSF positive in immunostained 
tumor sections (Kowalska et al. 2012; Zheng et al. 1999). However, the measured M-CSF 
amounts in the lymphoma CM and the resulting macrophage numbers also indicated the 
involvement of other factors to support the differentiation. GM-CSF was expressed by three 
cHL cell lines in this study and is known to contribute to macrophage differentiation. 
However, in vivo expression was not found on cHL tumor sections (Merz et al. 1991). Another 
factor known to support macrophage differentiation is VEGF-A (Sato et al. 2008; Yan et al. 
2017). VEGF-A was previously reported to be expressed in immunostained cHL patient 
samples (Doussis-Anagnostopoulou et al. 2002). We also detected VEGFA in L-428 and HBL-1 
cells. Hence, VEGF-A might account in vitro as well as in vivo for macrophage differentiation. 
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Besides promoting the developmental changes and polarization of monocytes toward 
macrophages factors in the CM might lead to improved survival or proliferation of monocytes. 
In this context, M-CSF again plays a role as it was shown to induce the proliferation of 
macrophages (Tymoszuk et al. 2014). IL-6, which is expressed on RNA level by L-428 and 
HBL-1 cells, was found to improve the survival of cultured monocytes (Roca et al. 2009). Since 
we also found a certain number of macrophages after differentiation with HBL-1 CM despite 
the fact that M-CSF was undetectable other factors such IL-6 or VEGF-A could account for 
these effects. A characteristic cytokine expressed in cHL cells is IL-13 that is also known to 
promote monocytes survival (McKenzie et al. 1993). Likewise an inhibited apoptosis can lead 
to high macrophage numbers after differentiation. A study showed that stimulation of 
monocytes with tumor derived exosomes resulted in impaired caspase activation (Song et al. 
2016).  
In conclusion, lymphoma cells secret numerous factors to support macrophage differentiation, 
notably, the expression of M-CSF and IL13 was found in cHL cells. Besides other factors were 
found to be expressed by L-428 but also HBL-1 cells that can contribute to differentiation and 
survival of monocytes. However, the high macrophage numbers yielding from differentiation 
with cHL CM show that specifically HRS cells secret a strong mixture of factors to support 
macrophage differentiation indicating a special requirement of these cells in the context of 
cHL. 
4.2 Phenotype and functions of cHL recruited macrophages 
4.2.1 Expression of cell surface markers and functional implications 
In this study we found that L-428 CM derived macrophages resemble M2 activated mature 
macrophages by analyses of the expression of several cell surface markers, CD68 and selected 
genes. This finding is in accordance with published data that widely proposes an M2-state of 
TAMs (see section 1.1.3). We identified several molecules to be higher expressed on L-428 CM 
derived macrophages compared to M-CSF derived cells these included CD11c, CD68, CD206, 
CD1a, CD80, CD40, PD-L1, CD33, CD44 and CD54. Notably, we found the highest differential 
expression between L-428 CM and M-CSF derived macrophages in CD206. Among the proteins 
analyzed were several involved in T cell interactions by antigen presentation and 
co-stimulation/-inhibition, i.e. HLA-DR, CD1a, CD80, CD86, CD40 and PD-L1, of which four 
were strongly expressed on L-428 CM derived cells. The inhibitory potential of macrophages 
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on T cell proliferation is a feature of M2 macrophages and was also found in tumor cell 
educated macrophages (Oishi et al. 2016; Huber et al. 2010; Yue et al. 2015; Lievense et al. 
2016; Duluc et al. 2007). The induction of PD-L1 may account for inhibition of cytotoxic T cell 
activity. Staining of cHL patient samples showed that the majority of tissue PD-L1 was 
expressed by macrophages and that these cells were surrounded by PD1+ T cells which 
presumably accounted for inhibitory interactions (Carey et al. 2017). Importantly, in our study 
CD40 a known co-stimulatory molecule was also upregulated in L-428 CM derived cells which 
rather suggests T cell activating properties. Of note CD40 is a common M1 marker for 
macrophages. We found L-428 CM derived macrophages to resemble M2 activated cells by the 
expression of several markers this suggests that M1 features were also acquired and that the 
cells have a distinct phenotype apart from those conventionally described for M1 or M2 
activated cells. Other receptors that interact with ligands on the T cell surface are CD80 and 
CD86. CD80 was upregulated and CD86 downregulated compared to monocytes. So far these 
receptors are described to expose redundant functions, whether these are stimulatory or 
inhibitory depend on the ligands on the T cell surface (Jonker et al. 2002). Thus, the 
significance of CD80/CD86 expression remains unclear. Interestingly, L-428 CM derived 
macrophages also expressed CD1a a molecule predominantly present on dendritic cells, but its 
expression on macrophages has also been described (Coventry & Heinzel 2004; Henkel et al. 
2004). It is proposed that CD1a+ DCs in the tumor present tumor glycolipids to T cells. 
Increased antigen presentation usually accounts for T cell activation. Consistent with this 
clinical studies found the presence of CD1a+ DCs to be associated with better prognosis 
(Coventry & Heinzel 2004). In cHL the presence of CD1a+ cells has also been described in one 
study and the cells have been assigned as DCs without staining of additional lineage markers 
(Tudor et al. 2014). Thus, so far nothing is known about the occurrence of CD1a+ 
macrophages in tumors.  
The notion that L-428 CM derived macrophages are involved in T cell interactions is strongly 
supported by the global gene expression analysis. Among the genes upregulated in this context 
were several HLA genes and genes encoding for co-stimulator and -inhibitory molecules such 
as CD80, CD86 and PD-L1. Again the set of genes found to be upregulated does not allow 
concluding the definite T cell response. Enhanced antigen presentation accompanied by 
co-stimulatory as well as -inhibitory signal could account for T cell activation as well as 
inhibition. Additionally, the differences in gene expression have to be validated whether they 
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translate into differences in protein expression. This does not necessarily have to be the case as 
seen e.g. in CD86 which was upregulated on gene expression level in L-428 CM derived cells 
compared to M-CSF macrophages but this difference was not seen in its surface expression.  
Taken together, our data strongly indicates a function of L-428 CM derived macrophages in 
T cell interaction. This would be in concordance with the observation that T cells are the 
predominant cellular fraction in the cHL TME. Clinical studies also suggest suppression of 
T cell function by macrophages. However, from our data the result of their interaction cannot 
be definitely predicted. Further investigations have to determine the effect of L-428 CM 
derived macrophages on T cells by applying direct interaction experiments with both cell 
types. 
4.2.2 CD206 expression and endocytic activity of cHL CM derived macrophages 
A principal finding of this study is the induction of CD206 expression and the corresponding 
changes in endocytic activities of cHL CM derived macrophages. Namely, we found the uptake 
of dextran and collagen was increased in L-428 CM derived cells compared to M-CSF cells 
which expressed less CD206 on their cell surface. As stated when introducing the mannose 
receptor family the sugar and collagen binding is mediated by different domains and the bent 
conformation of the receptor might account for specific binding of glycosylated collagens (see 
section 1.2.1). Thus, the enhanced endocytic activity could under physiological conditions 
account for binding and uptake of specific glycosylated collagens. Additionally, on L-428 CM 
derived macrophages we found a higher expression of adhesion molecules, i.e. CD11c, CD33, 
CD44 and CD54 compared to M-CSF derived cells. This further indicates that L-428 CM 
macrophages might expose functions in matrix interaction and organization. Matrix 
remodeling is a common process in tumor development and the tumor stroma is characterized 
by profound proteolytic degradation (Luciani et al. 1998). In a mouse model of lung cancer it 
was shown that matrix degradation and subsequent collagen uptake by macrophages was 
partly dependent on CD206 (Madsen et al. 2017). In addition to the high uptake of CD206 
substrates in cHL CM derived cells we found high MMP-9 secretion, yet not increased 
compared to M-CSF derived cells. These findings suggest that matrix remodeling by 
macrophages might also be functionally relevant in cHL. Altered matrix composition has been 
shown to account for tumor growth and metastasis. A study found that matrix stiffness can 
modulate cancer cell proliferation in an in vitro 3D model (Alonso-Nocelo et al. 2018). 
Additionally, degradation of the basal membrane by macrophages is an important step in 
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cancer cell extravasion as seen in a mouse model of mammary tumors (Wang et al. 2002). 
Using direct co-culture of L-428 cells with macrophages in a CAM assay we found tumors to be 
smaller. Stained sections revealed that co-culture tumors contained fewer cells. This argues 
against improved proliferation of the cells and benefits in tumor progression by macrophage 
addition. However, reduced cell numbers could be the result of cells disseminating from the 
application spot. A study using pancreatic cancer cells in a CAM assay found an accumulation 
of disseminating cells in the chicken embryo lung and liver (Zijlstra et al. 2008). Hence, 
further investigation on the cause of the reduction of the tumor mass should include the 
detection of tumor cells at distant sites in the egg. 
Another potential function of enhanced uptake of CD206 targets is the presentation of the 
corresponding antigens to T cells. Thus far this was shown to occur in CD206+ DCs (Burgdorf 
et al. 2006). Macrophages are also antigen presenting cells able to activate T cells (Hilhorst et 
al. 2014). Improved antigen presentation as a result of increased CD206 expression is 
therefore possible. Noteworthy in this context is that CD206 also binds to glycolipids which 
can be presented by CD1a, a protein we also found to be upregulated on L-428 CM derived 
macrophages (Rawlings et al. 2004). Antigen presentation to T cells usually results in T cell 
activation arguing against immune suppressive functions that are proposed for TAMs. 
However, in combination with co-inhibitory signals it might lead to T cell exhaustion 
impairing the anti-tumor defense of T cells (Wherry 2011). Further investigations have to 
assess whether the increased CD206 expression leads to enhanced antigen presentation. The 
T cell response in this case still depends on the co-stimulatory and -inhibitory repertoire of the 
cells as already depicted in the previous section. Further studies of these effects would again 
require direct interaction experiments of macrophages and T cells and additionally cytotoxic 
killing assays of stimulated CD8+ T cells. 
4.3 Factors inducing CD206 expression on cHL derived macrophages 
We hypothesized that IL-13 expressed by cHL cells is responsible for increased CD206 
expression on macrophages. The M2 activation of macrophages in vitro is usually achieved by 
stimulation with IL-4, IL-13 or a combination which leads to CD206 expression (Doyle et al. 
1994). Here we could show that IL-13 leads to an induction of MRC1 gene expression within 
6 h and increased expression on the cell surface within 24 h on monocytes which was 
otherwise absent. This indicates that IL-13 in the cHL CM is a critical factor to increase MRC1 
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expression in CM generated macrophages. Strikingly, only cell lines that expressed IL13 were 
found to induce MRC1 expression in monocytes within 6 h. However, since the MRC1 
expression after L-428 CM stimulation was stronger increased than with IL-13 alone it is 
reasonable to propose that additional factors secreted by cHL cells are involved in MRC1 
induction. Notably, it was found that GM-CSF can induce MRC1 expression in human 
monocytes (Däbritz et al. 2015). We detected CSF2 gene expression in three cHL cell lines 
suggesting GM-CSF could also be involved in the MRC1 induction in these experiments. 
Another factor widely known to induce MRC1 expression is IL-4 (Martinez et al. 2006). 
However, no gene expression was found by RNA-Seq in L-428 and HBL-1 cells. Thus, in 
L-428 CM which highly induced MRC1 expression this factor does not play a role. Additionally, 
we observed that after inhibition of JAK1 and JAK2 MRC1 expression in monocytes was 
abolished. IL-13 binds to an IL4Rα-IL13Rα heterodimer which intracellularly binds to JAK1, 
JAK2 and TYK2. The absence of MRC1 expression after Ruxolitinib treatment indicates JAK1 
or JAK2 rather than TYK2 are essential for the induction of gene expression. Likewise this is 
the case in L-428 CM stimulated cells since also here MRC1 expression was absent after 
Ruxolitinib treatment. Activated JAKs subsequently phosphorylate STAT proteins which upon 
phosphorylation enter the nucleus and regulate gene transcription (Rawlings et al. 2004). 
Little is known about the transcriptional regulation of MRC1 including whether it is regulated 
by STATs. A described mechanism for the induction of MRC1 expression after IL-13 
stimulation is via phosphorylation of phospholipase A2 (PLA2) which leads to enhanced 
production of prostaglandins and activation of peroxisome proliferator-activated receptor γ 
(PPARγ)(Coste et al. 2003). This suggests that rather than STATs PPARγ mediates the 
transcriptional control of MRC1. Further investigation on the activation of STATs or PLA2 and 
consequently PPARγ as well as their binding to the MRC1 promoter region have to clarify the 
specific mechanism of MRC1 induction by IL-13 stimulation. Additionally, blocking of the IL-13 
receptor or IL-13 depletion from the lymphoma CM could reveal the specific impact of IL-13 in 
the CM on MRC1 expression in monocytes. 
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5 Summary and Conclusion 
A rich and vast TME is a characteristic of cHL and interactions between bystander cells and 
malignant HRS cells are essential for tumor progression. In the presented study we showed 
that HRS cells secret factors to attract monocytes and macrophages. The recruited cells are 
either differentiated or repolarized, respectively. Recruitment of macrophages and 
differentiation of monocytes was also found with DLBCL CM, however, to a lesser extent. 
Further investigations on the phenotype of cHL derived cells showed their M2-like activation 
state and upregulation of several cell surface markers which indicates functions in T cell 
communication and tissue remodeling. This supports the view of an active recruitment of 
myeloid cells into the tumor and their manipulation to exhibit specific functions. Studies on 
functional properties revealed an enhanced endocytic activity that was in accordance with a 
high CD206 expression on these cells. The high MMP-9 secretion and the changes in the tumor 
formation of L-428 cells by addition of macrophages provided further evidence that cHL 
derived macrophages are involved in tissue remodeling. Ongoing analyses have to evaluate the 
role of this in tumor progression especially an improved dissemination and metastasis is 
suggested. Another indicated function of cHL CM derived macrophages is their interplay with 
T cells. Further analyses are necessary to confirm this proposed function in T cell interaction 
and whether it is inhibitory or stimulatory. Among the factors produced by cHL cells we found 
that IL-13 can induce CD206 expression. Identification of the mediating factors that leads to 
the observed phenotype of cHL derived macrophages could further improve the understanding 
of macrophage recruitment into the TME. 
Analyses of interactions of malignant cells with their TME have proven valuable to dissect new 
therapeutic targets and to develop anti-cancer therapies. This study has provided evidence on 
interactions of HRS cells with macrophages focusing on the manipulation of macrophages by 
HRS cell secreted factors. Additional work has to be done to fully understand the mutual 
interplay of these two cell types, to define the molecular mediators and whether a disruption 
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Figure A-19: Expression of selected cytokines and chemokines in L-428 and HBL-1 cells by RNA-seq. 
Presentation of normalized reads of selected cytokines and chemokines detected by RNA-Seq in L-428 and HBL-1 
cells (mean, n = 2). 
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Figure A-20: Heatmap of differentially expressed genes between L-428 CM, M-CSF and HBL-1 CM derived 
macrophages. 
Heatmap of all genes that were differentially expressed in L-428 CM derived macrophages compared to M-CSF cells 
by Log2FC ≥ 1 and Log2FC ≤ -1 in all three donors (#1, #2, #3) and compared to HBL-1 CM derived cells. 
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Figure A-21: GO term enrichment clusters calculated by DAVID for differentially expressed genes between 
L-428 CM and M-CSF derived macrophages. 
Top five GO term enrichment clusters for differentially expressed genes between L-428 CM and M-CSF derived 
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Figure A-22: GO term and InterPro enrichment clusters calculated by DAVID for differentially expressed 
genes between L-428 CM and M-CSF derived macrophages. 
Top five GO term enrichment clusters for differentially expressed genes between L-428 CM and M-CSF derived 
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